EuRBPDB

Basic Information
Cancer Related Information

Description

RBPome

Literatures

Expression

Transcripts

Gene Model

Pathways

Phenotypes

GWAS

PPI

Gene Ontology

Description

Ensembl ID: ENSG00000198793 (Gene tree)
Gene ID: 2475
Gene Symbol: MTOR
Alias: RAFT1|RAPT1|FLJ44809|FRAP|FRAP2|FRAP1
Full Name: mechanistic target of rapamycin kinase
Gene Type: protein_coding
Species: Homo_sapiens
Status: confidence
Strand: Minus strand
Length: 156,027 bases
Position: chr1:11,106,531-11,262,557
Accession: 3942
RBP type: non-canonical RBP
Summary: The protein encoded by this gene belongs to a family of phosphatidylinositol kinase-related kinases. These kinases mediate cellular responses to stresses such as DNA damage and nutrient deprivation. This protein acts as the target for the cell-cycle arrest and immunosuppressive effects of the FKBP12-rapamycin complex. The ANGPTL7 gene is located in an intron of this gene. [provided by RefSeq, Sep 2008]

RNA binding proteome (RBPome)

PID	Title	Method	Time	Author	Doi
30607034	Comprehensive identification of RNA protein interactions in any organism using orthogonal organic phase separation (OOPS)	OOPS & HEK293	2019 Jan 3	Queiroz RML	DOI: 10.1038/s41587-018-0001-2
30607034	Comprehensive identification of RNA protein interactions in any organism using orthogonal organic phase separation (OOPS)	OOPS & U2OS	2019 Jan 3	Queiroz RML	DOI: 10.1038/s41587-018-0001-2

Literatures on RNA binding capacity

PID	Title	Article	Time	Author	Doi
30939964	Retinoic acid worsens ATG10-dependent autophagy impairment in TBK1-mutant hiPSC-derived motoneurons through SQSTM1/p62 accumulation.	Autophagy	2019 Apr 2:1-19	Catanese A	doi: 10.1080/15548627.2019.1589257
20028979	Activation of the Ran GTPase is subject to growth factor regulation and can give rise to cellular transformation.	J Biol Chem	2010 Feb 19	Ly TK	doi: 10.1074/jbc.M109.071886
18462695	A hierarchical network controls protein translation during murine embryonic stem cell self-renewal and differentiation.	Cell Stem Cell	2008 May 8	Sampath P	doi: 10.1016/j.stem.2008.03.013.
17376031	Signalling to translation: how signal transduction pathways control the protein synthetic machinery.	Biochem J	2007 Apr 15	Proud CG	-
21576258	mTOR phosphorylates IMP2 to promote IGF2 mRNA translation by internal ribosomal entry.	Genes Dev	2011 Jun 1	Dai N	doi: 10.1101/gad.2042311
21454539	Phosphomimetic substitution of heterogeneous nuclear ribonucleoprotein A1 at serine 199 abolishes AKT-dependent internal ribosome entry site-transacting factor (ITAF) function via effects on strand annealing and results in mammalian target of rapamycin complex 1 (mTORC1) inhibitor sensitivity.	J Biol Chem	2011 May 6	Martin J	doi: 10.1074/jbc.M110.205096
24879147	Identification of a novel MTOR activator and discovery of a competing endogenous RNA regulating autophagy in vascular endothelial cells.	Autophagy	2014 Jun	Ge D	doi: 10.4161/auto.28363.
23444380	mTOR-dependent proliferation defect in human ES-derived neural stem cells affected by myotonic dystrophy type 1.	J Cell Sci	2013 Apr 15	Denis JA	doi: 10.1242/jcs.116285
26120033	RNA Binding Protein Nanos2 Organizes Post-transcriptional Buffering System to Retain Primitive State of Mouse Spermatogonial Stem Cells.	Dev Cell	2015 Jul 6	Zhou Z	doi: 10.1016/j.devcel.2015.05.014
25944900	Mammalian Target of Rapamycin (mTOR) Tagging Promotes Dendritic Branch Variability through the Capture of Ca2+/Calmodulin-dependent Protein Kinase II α (CaMKIIα) mRNAs by the RNA-binding Protein HuD.	J Biol Chem	2015 Jun 26	Sosanya NM	doi: 10.1074/jbc.M114.599399
25770584	Che-1-induced inhibition of mTOR pathway enables stress-induced autophagy.	EMBO J	2015 May 5	Desantis A	doi: 10.15252/embj.201489920
25776557	Sam68 Regulates S6K1 Alternative Splicing during Adipogenesis.	Mol Cell Biol	2015 Jun 1	Song J	doi: 10.1128/MCB.01488-14
28493559	mTOR referees memory and disease through mRNA repression and competition.	FEBS Lett	2017 Jun	Raab-Graham KF	doi: 10.1002/1873-3468.12675
30131676	The Intracellular Cleavage Product of the NG2 Proteoglycan Modulates Translation and Cell-Cycle Kinetics via Effects on mTORC1/FMRP Signaling.	Front Cell Neurosci	2018 Aug 7	Nayak T	doi: 10.3389/fncel.2018.00231
30917721	Mitochondrial respiratory chain deficiency inhibits lysosomal hydrolysis.	Autophagy	2019 Sep	Fernandez-Mosquera L	doi: 10.1080/15548627.2019.1586256
17255101	p21-activated kinase 1 is activated through the mammalian target of rapamycin/p70 S6 kinase pathway and regulates the replication of hepatitis C virus in human hepatoma cells.	J Biol Chem	2007 Apr 20	Ishida H	-
30209975	Thyroid hormone (T3) stimulates brown adipose tissue activation via mitochondrial biogenesis and MTOR-mediated mitophagy.	Autophagy	2019 Jan	Yau WW	doi: 10.1080/15548627.2018.1511263
30973085	Rutin hydrate inhibits apoptosis in the brains of cadmium chloride-treated rats via preserving the mitochondrial integrity and inhibiting endoplasmic reticulum stress.	Neurol Res	2019 Jul	Mostafa DG	doi: 10.1080/01616412.2019.1596206
27947744	-	-	-	-	-
16049009	hVps34 is a nutrient-regulated lipid kinase required for activation of p70 S6 kinase.	J Biol Chem	2005 Sep 23	Byfield MP	-
17329400	ASCT2 silencing regulates mammalian target-of-rapamycin growth and survival signaling in human hepatoma cells.	Am J Physiol Cell Physiol	2007 Jul	Fuchs BC	-
20876744	Rapamycin regulates stearoyl CoA desaturase 1 expression in breast cancer.	Mol Cancer Ther	2010 Oct	Luyimbazi D	doi: 10.1158/1535-7163.MCT-09-0980
24189100	MTOR inhibition attenuates DNA damage and apoptosis through autophagy-mediated suppression of CREB1.	Autophagy	2013 Dec	Wang Y	doi: 10.4161/auto.26447
19414512	Life-span extension in mice by preweaning food restriction and by methionine restriction in middle age.	J Gerontol A Biol Sci Med Sci	2009 Jul	Sun L	doi: 10.1093/gerona/glp051
18842593	Rheb and mTOR regulate neuronal polarity through Rap1B.	J Biol Chem	2008 Nov 28	Li YH	doi: 10.1074/jbc.M802431200
22363130	Epithelial-to-mesenchymal and mesenchymal-to-epithelial transitions in the colon.	World J Gastroenterol	2012 Feb 21	Sipos F	doi: 10.3748/wjg.v18.i7.601.
23443539	Translation of HTT mRNA with expanded CAG repeats is regulated by the MID1-PP2A protein complex.	Nat Commun	2013	Krauss S	doi: 10.1038/ncomms2514.
28821580	Cap-independent translation ensures mTOR expression and function upon protein synthesis inhibition.	RNA	2017 Nov	Marques-Ramos A	doi: 10.1261/rna.063040.117
29929416	MoSnt2-dependent deacetylation of histone H3 mediates MoTor-dependent autophagy and plant infection by the rice blast fungus Magnaporthe oryzae.	Autophagy	2018	He M	doi: 10.1080/15548627.2018.1458171
30488423	Protective effect of microRNA-224 on acute lower extremity ischemia through activation of the mTOR signaling pathway via CHOP in mice.	J Cell Physiol	2019 Jun	Chen YX	doi: 10.1002/jcp.27550
30541828	Autophagy Promotes Replication of Influenza A Virus In Vitro.	J Virol	2019 Feb 5	Wang R	doi: 10.1128/JVI.01984-18
30616697	Leucine regulates α-amylase and trypsin synthesis in dairy calf pancreatic tissue in vitro via the mammalian target of rapamycin signalling pathway.	Animal	2019 Jan 8:1-8	Guo L	doi: 10.1017/S1751731118003683
30942461	Identification of suitable reference genes for gene expression studies in rat skeletal muscle following sciatic nerve crush injury.	Mol Med Rep	2019 May	Wang X	doi: 10.3892/mmr.2019.10102
30982460	HIF1A and NFAT5 coordinate Na+-boosted antibacterial defense via enhanced autophagy and autolysosomal targeting.	Autophagy	2019 Apr 14:1-18	Neubert P	doi: 10.1080/15548627.2019.1596483

Expression

Transcripts

Transcript ID	Name	Length	RefSeq ID	Protein ID	Length	RefSeq ID	UniportKB ID
ENST00000473471	MTOR-204	862	-	-	- (aa)	-	-
ENST00000476768	MTOR-205	610	-	-	- (aa)	-	-
ENST00000455339	MTOR-203	694	-	ENSP00000398745	161 (aa)	-	B1AKQ2
ENST00000495435	MTOR-207	2356	-	-	- (aa)	-	-
ENST00000376838	MTOR-202	4017	-	ENSP00000366034	754 (aa)	-	B1AKP8
ENST00000361445	MTOR-201	8677	XM_005263438	ENSP00000354558	2549 (aa)	XP_005263495	P42345
ENST00000490931	MTOR-206	1111	-	-	- (aa)	-	-

Gene Model

Click here to download ENSG00000198793's gene model file

Pathways

Pathway ID	Pathway Name	Source
hsa01521	EGFR tyrosine kinase inhibitor resistance	KEGG
hsa01522	Endocrine resistance	KEGG
hsa04012	ErbB signaling pathway	KEGG
hsa04066	HIF-1 signaling pathway	KEGG
hsa04072	Phospholipase D signaling pathway	KEGG
hsa04136	Autophagy - other	KEGG
hsa04140	Autophagy - animal	KEGG
hsa04150	mTOR signaling pathway	KEGG
hsa04151	PI3K-Akt signaling pathway	KEGG
hsa04152	AMPK signaling pathway	KEGG
hsa04211	Longevity regulating pathway	KEGG
hsa04213	Longevity regulating pathway - multiple species	KEGG
hsa04218	Cellular senescence	KEGG
hsa04371	Apelin signaling pathway	KEGG
hsa04630	JAK-STAT signaling pathway	KEGG
hsa04659	Th17 cell differentiation	KEGG
hsa04714	Thermogenesis	KEGG
hsa04910	Insulin signaling pathway	KEGG
hsa04919	Thyroid hormone signaling pathway	KEGG
hsa04920	Adipocytokine signaling pathway	KEGG
hsa04930	Type II diabetes mellitus	KEGG
hsa04931	Insulin resistance	KEGG
hsa05163	Human cytomegalovirus infection	KEGG
hsa05165	Human papillomavirus infection	KEGG
hsa05167	Kaposi sarcoma-associated herpesvirus infection	KEGG
hsa05168	Herpes simplex virus 1 infection	KEGG
hsa05170	Human immunodeficiency virus 1 infection	KEGG
hsa05200	Pathways in cancer	KEGG
hsa05205	Proteoglycans in cancer	KEGG
hsa05206	MicroRNAs in cancer	KEGG
hsa05210	Colorectal cancer	KEGG
hsa05212	Pancreatic cancer	KEGG
hsa05214	Glioma	KEGG
hsa05215	Prostate cancer	KEGG
hsa05221	Acute myeloid leukemia	KEGG
hsa05224	Breast cancer	KEGG
hsa05225	Hepatocellular carcinoma	KEGG
hsa05226	Gastric cancer	KEGG
hsa05230	Central carbon metabolism in cancer	KEGG
hsa05231	Choline metabolism in cancer	KEGG

Phenotypes

ensgID	Trait	pValue	Pubmed ID
ENSG00000198793	Pulse Wave Analysis	1.078e-006	-
ENSG00000198793	Corneal Topography	4E-13	21665993
ENSG00000198793	Body Mass Index	9E-6	25673413
ENSG00000198793	Body Mass Index	2E-6	25673413
ENSG00000198793	Corneal Topography	6E-18	24963161

GWAS

ensgID	SNP	Chromosome	Position	SNP-risk	Trait	PubmedID	95% CI	Or or BEAT	EFO ID
ENSG00000198793	rs28991009	1	11193627	G	Intraocular pressure	29617998	[0.58-0.89] unit increase	0.7319	EFO_0004695
ENSG00000198793	rs74225573	1	11220937	C	Corneal curvature	24963161	[0.12-0.20] unit increase	0.16	EFO_0004345
ENSG00000198793	rs75077113	1	11154525	A	Heel bone mineral density	28869591	[0.016-0.03] unit increase	0.022928	EFO_0009270
ENSG00000198793	rs75077113	1	11154525	A	Heel bone mineral density	28869591	[0.012-0.032] unit increase	0.0217809	EFO_0009270
ENSG00000198793	rs17036350	1	11111169	T	Corneal curvature	21665993	[0.11-0.25] unit increase	0.178	EFO_0004345
ENSG00000198793	rs75077113	1	11154525	?	Heel bone mineral density	30048462	[0.016-0.025] unit increase	0.0204864	EFO_0009270
ENSG00000198793	rs184689679	1	11149725	?	Balding type 1	30595370			EFO_0007825
ENSG00000198793	rs2791643	1	11147212	?	Body mass index	30595370			EFO_0004340
ENSG00000198793	rs2261434	1	11110074	?	Heel bone mineral density	30595370			EFO_0009270

Protein-Protein Interaction (PPI)

Clik here to download ENSG00000198793's network

* RBP PPI network refers to all genes directly bind to RBP

Gene Ontology

Go ID	Go_term	PubmedID	Evidence	Category
GO:0000139	Golgi membrane	-	IEA	Component
GO:0001030	RNA polymerase III type 1 promoter DNA binding	20233713.	IDA	Function
GO:0001031	RNA polymerase III type 2 promoter DNA binding	20233713.	IDA	Function
GO:0001032	RNA polymerase III type 3 promoter DNA binding	20233713.	IDA	Function
GO:0001156	TFIIIC-class transcription factor complex binding	20543138.	IDA	Function
GO:0001558	regulation of cell growth	18762023.	IDA	Process
GO:0001933	negative regulation of protein phosphorylation	-	IEA	Process
GO:0001934	positive regulation of protein phosphorylation	20233713.	IDA	Process
GO:0001938	positive regulation of endothelial cell proliferation	-	IEA	Process
GO:0002296	T-helper 1 cell lineage commitment	-	IEA	Process
GO:0003007	heart morphogenesis	-	IEA	Process
GO:0003179	heart valve morphogenesis	-	IEA	Process
GO:0004672	protein kinase activity	12150926.	IDA	Function
GO:0004674	protein serine/threonine kinase activity	22768106.	EXP	Function
GO:0004674	protein serine/threonine kinase activity	21873635.	IBA	Function
GO:0004674	protein serine/threonine kinase activity	12718876.15467718.	IDA	Function
GO:0004674	protein serine/threonine kinase activity	-	TAS	Function
GO:0005515	protein binding	10089303.11438723.12150925.12150926.12408816.15467718.16915281.17148612.17461779.17565979.18339839.18550814.18566587.18955708.19446321.19619545.19875983.20080789.20543138.20562859.20864032.21045808.21376236.21471201.21614075.22307628.22424946.22664266.23027611.23263282.23394946.23524951.23636326.23953116.24036451.24375676.24670654.25241761.25446900.25657994.25686248.26348909.26593251.26678875.26787466.27043084.29750193.29997244.	IPI	Function
GO:0005524	ATP binding	-	IEA	Function
GO:0005634	nucleus	21873635.	IBA	Component
GO:0005654	nucleoplasm	-	TAS	Component
GO:0005737	cytoplasm	11853878.20381137.	IDA	Component
GO:0005741	mitochondrial outer membrane	-	IEA	Component
GO:0005764	lysosome	20381137.25936802.29750193.	IDA	Component
GO:0005764	lysosome	22424946.	IMP	Component
GO:0005765	lysosomal membrane	17897319.	HDA	Component
GO:0005789	endoplasmic reticulum membrane	-	IEA	Component
GO:0005829	cytosol	-	TAS	Component
GO:0005979	regulation of glycogen biosynthetic process	-	IEA	Process
GO:0006112	energy reserve metabolic process	-	IEA	Process
GO:0006207	'de novo' pyrimidine nucleobase biosynthetic process	-	IEA	Process
GO:0006468	protein phosphorylation	12150926.15467718.18925875.	IDA	Process
GO:0006468	protein phosphorylation	17028174.	IMP	Process
GO:0007050	cell cycle arrest	-	TAS	Process
GO:0007281	germ cell development	-	IEA	Process
GO:0007420	brain development	-	IEA	Process
GO:0007569	cell aging	-	IEA	Process
GO:0007584	response to nutrient	17028174.	IMP	Process
GO:0007616	long-term memory	-	IEA	Process
GO:0008361	regulation of cell size	22424946.	IMP	Process
GO:0008542	visual learning	-	IEA	Process
GO:0009267	cellular response to starvation	28223137.	IDA	Process
GO:0009791	post-embryonic development	-	IEA	Process
GO:0010507	negative regulation of autophagy	21873635.	IBA	Process
GO:0010507	negative regulation of autophagy	22424946.	IMP	Process
GO:0010507	negative regulation of autophagy	-	ISS	Process
GO:0010592	positive regulation of lamellipodium assembly	-	IEA	Process
GO:0010628	positive regulation of gene expression	17028174.	IMP	Process
GO:0010718	positive regulation of epithelial to mesenchymal transition	27919618.	IMP	Process
GO:0010831	positive regulation of myotube differentiation	-	IEA	Process
GO:0012505	endomembrane system	18497260.22424946.	IDA	Component
GO:0014042	positive regulation of neuron maturation	-	IEA	Process
GO:0014736	negative regulation of muscle atrophy	-	IEA	Process
GO:0014823	response to activity	-	IEA	Process
GO:0016020	membrane	19946888.	HDA	Component
GO:0016020	membrane	11853878.	IDA	Component
GO:0016241	regulation of macroautophagy	-	TAS	Process
GO:0016242	negative regulation of macroautophagy	21873635.	IBA	Process
GO:0016242	negative regulation of macroautophagy	25327288.	IDA	Process
GO:0016301	kinase activity	15467718.25327288.	IDA	Function
GO:0016301	kinase activity	11853878.	TAS	Function
GO:0016310	phosphorylation	11853878.25327288.	IDA	Process
GO:0016605	PML body	-	ISS	Component
GO:0018105	peptidyl-serine phosphorylation	20537536.23728790.	IMP	Process
GO:0018107	peptidyl-threonine phosphorylation	-	IEA	Process
GO:0019901	protein kinase binding	-	IEA	Function
GO:0019904	protein domain specific binding	-	IEA	Function
GO:0021510	spinal cord development	-	IEA	Process
GO:0030163	protein catabolic process	11853878.	TAS	Process
GO:0030425	dendrite	-	IEA	Component
GO:0030838	positive regulation of actin filament polymerization	-	IEA	Process
GO:0031397	negative regulation of protein ubiquitination	-	IEA	Process
GO:0031529	ruffle organization	-	IEA	Process
GO:0031641	regulation of myelination	-	IEA	Process
GO:0031667	response to nutrient levels	29750193.	IDA	Process
GO:0031669	cellular response to nutrient levels	-	ISS	Process
GO:0031929	TOR signaling	15467718.17028174.18762023.26018084.29750193.	IMP	Process
GO:0031929	TOR signaling	23778976.	NAS	Process
GO:0031931	TORC1 complex	21873635.	IBA	Component
GO:0031931	TORC1 complex	12150926.12718876.15467718.18925875.	IDA	Component
GO:0031931	TORC1 complex	20537536.	IMP	Component
GO:0031932	TORC2 complex	21873635.	IBA	Component
GO:0031932	TORC2 complex	15467718.18925875.	IDA	Component
GO:0031998	regulation of fatty acid beta-oxidation	-	IEA	Process
GO:0032095	regulation of response to food	-	IEA	Process
GO:0032148	activation of protein kinase B activity	-	TAS	Process
GO:0032516	positive regulation of phosphoprotein phosphatase activity	28386764.	TAS	Process
GO:0032868	response to insulin	-	IEA	Process
GO:0032956	regulation of actin cytoskeleton organization	15467718.	IMP	Process
GO:0034198	cellular response to amino acid starvation	22424946.	IDA	Process
GO:0035176	social behavior	-	IEA	Process
GO:0035264	multicellular organism growth	-	IEA	Process
GO:0038202	TORC1 signaling	21873635.	IBA	Process
GO:0038202	TORC1 signaling	28223137.	IDA	Process
GO:0038202	TORC1 signaling	12718876.22424946.	IMP	Process
GO:0042060	wound healing	-	IEA	Process
GO:0042220	response to cocaine	-	IEA	Process
GO:0042802	identical protein binding	11438723.24670654.	IPI	Function
GO:0043022	ribosome binding	-	IEA	Function
GO:0043025	neuronal cell body	-	IEA	Component
GO:0043087	regulation of GTPase activity	-	IEA	Process
GO:0043200	response to amino acid	18497260.	IDA	Process
GO:0043276	anoikis	23778976.	NAS	Process
GO:0043278	response to morphine	-	IEA	Process
GO:0043610	regulation of carbohydrate utilization	-	IEA	Process
GO:0045182	translation regulator activity	-	IEA	Function
GO:0045429	positive regulation of nitric oxide biosynthetic process	-	IEA	Process
GO:0045670	regulation of osteoclast differentiation	-	ISS	Process
GO:0045727	positive regulation of translation	18762023.	IDA	Process
GO:0045792	negative regulation of cell size	-	IEA	Process
GO:0045945	positive regulation of transcription by RNA polymerase III	20233713.	IMP	Process
GO:0046777	protein autophosphorylation	15467718.	IDA	Process
GO:0046889	positive regulation of lipid biosynthetic process	18762023.	IMP	Process
GO:0048255	mRNA stabilization	-	IEA	Process
GO:0048661	positive regulation of smooth muscle cell proliferation	-	IEA	Process
GO:0048714	positive regulation of oligodendrocyte differentiation	-	IEA	Process
GO:0050731	positive regulation of peptidyl-tyrosine phosphorylation	-	IEA	Process
GO:0050882	voluntary musculoskeletal movement	-	IEA	Process
GO:0051219	phosphoprotein binding	11853878.	IPI	Function
GO:0051496	positive regulation of stress fiber assembly	-	IEA	Process
GO:0051549	positive regulation of keratinocyte migration	27919618.	IMP	Process
GO:0051897	positive regulation of protein kinase B signaling	-	IEA	Process
GO:0055013	cardiac muscle cell development	-	IEA	Process
GO:0060048	cardiac muscle contraction	-	IEA	Process
GO:0060135	maternal process involved in female pregnancy	-	IEA	Process
GO:0060252	positive regulation of glial cell proliferation	-	IEA	Process
GO:0060999	positive regulation of dendritic spine development	-	IEA	Process
GO:0061051	positive regulation of cell growth involved in cardiac muscle cell development	-	IEA	Process
GO:0070885	negative regulation of calcineurin-NFAT signaling cascade	-	IEA	Process
GO:0071230	cellular response to amino acid stimulus	22424946.	IDA	Process
GO:0071233	cellular response to leucine	22424946.	IDA	Process
GO:0071456	cellular response to hypoxia	-	ISS	Process
GO:0090335	regulation of brown fat cell differentiation	-	IEA	Process
GO:0090559	regulation of membrane permeability	-	IEA	Process
GO:0098978	glutamatergic synapse	-	IEA	Component
GO:0099524	postsynaptic cytosol	-	IEA	Component
GO:0099547	regulation of translation at synapse, modulating synaptic transmission	-	IEA	Process
GO:1900034	regulation of cellular response to heat	-	TAS	Process
GO:1901216	positive regulation of neuron death	-	IEA	Process
GO:1901838	positive regulation of transcription of nucleolar large rRNA by RNA polymerase I	24036451.	IMP	Process
GO:1903691	positive regulation of wound healing, spreading of epidermal cells	27919618.	IMP	Process
GO:1904000	positive regulation of eating behavior	-	IEA	Process
GO:1904056	positive regulation of cholangiocyte proliferation	-	IEA	Process
GO:1904058	positive regulation of sensory perception of pain	-	IEA	Process
GO:1904193	negative regulation of cholangiocyte apoptotic process	-	IEA	Process
GO:1904197	positive regulation of granulosa cell proliferation	-	IEA	Process
GO:1904206	positive regulation of skeletal muscle hypertrophy	-	IEA	Process
GO:1904213	negative regulation of iodide transmembrane transport	-	IEA	Process
GO:1904690	positive regulation of cytoplasmic translational initiation	28386764.	TAS	Process
GO:1990253	cellular response to leucine starvation	22424946.	IDA	Process

Cancer associated literatures

PID	Title	Article	Time	Author	Doi
24323026	Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.	J Clin Oncol	2014 Jan 10	Gandhi L	doi: 10.1200/JCO.2012.47.2787
26506516	Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer.	Oncotarget	2015 Dec 8	Qi W	doi: 10.18632/oncotarget.5659.
25491778	The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.	Breast Cancer Res Treat	2015 Jan	Bean JR	doi: 10.1007/s10549-014-3201-6
20009539	Effects of combined inhibition of MEK and mTOR on downstream signaling and tumor growth in pancreatic cancer xenograft models.	Cancer Biol Ther	2009 Oct	Chang Q	-
21744334	Selective gene expression profiling of mTOR-associated tumor suppressor and oncogenes in ovarian cancer.	Folia Histochem Cytobiol	2011	Lauda??ski P	-
25962638	Butein suppresses cervical cancer growth through the PI3K/AKT/mTOR pathway.	Oncol Rep	2015 Jun	Bai X	doi: 10.3892/or.2015.3922
25478811	mTOR and PDGF pathway blockade inhibits liver metastasis of colorectal cancer by modulating the tumor microenvironment.	Am J Pathol	2015 Feb	Yuge R	doi: 10.1016/j.ajpath.2014.10.014
20030877	Controversies in breast cancer: the mammalian target of rapamycin as a target for breast cancer therapy.	Breast Cancer Res	2009	Di Cosimo S	doi: 10.1186/bcr2444
25046358	A novel small-molecule compound diaporine A inhibits non-small cell lung cancer growth by regulating miR-99a/mTOR signaling.	Cancer Biol Ther	2014 Oct	Song Y	doi: 10.4161/cbt.29925
22907434	ADAMTS9 is a functional tumor suppressor through inhibiting AKT/mTOR pathway and associated with poor survival in gastric cancer.	Oncogene	2013 Jul 11	Du W	doi: 10.1038/onc.2012.359
20226010	Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo.	Mol Cancer	2010 Mar 12	Roulin D	doi: 10.1186/1476-4598-9-57.
26523512	Propofol promotes cell apoptosis via inhibiting HOTAIR mediated mTOR pathway in cervical cancer.	Biochem Biophys Res Commun	2015 Dec 25	Zhang D	doi: 10.1016/j.bbrc.2015.10.129
28377226	Aquaporin 3 facilitates tumor growth in pancreatic cancer by modulating mTOR signaling.	Biochem Biophys Res Commun	2017 May 13	Huang X	doi: 10.1016/j.bbrc.2017.03.168
27153561	Targeting carbonic anhydrase IX improves the anti-cancer efficacy of mTOR inhibitors.	Oncotarget	2016 Jun 14	Faes S	doi: 10.18632/oncotarget.9134.
29233126	Positive prognostic value of HER2-HER3 co-expression and p-mTOR in gastric cancer patients.	BMC Cancer	2017 Dec 12	Cao GD	doi: 10.1186/s12885-017-3851-y.
27507059	Superior efficacy of co-treatment with the dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A against NSCLC.	Oncotarget	2016 Sep 13	Piao J	doi: 10.18632/oncotarget.11109.
21266827	Alteration of REDD1-mediated mammalian target of rapamycin pathway and hypoxia-inducible factor-1α regulation in human breast cancer.	Pathobiology	2010	Koo JS	doi: 10.1159/000320936
24469052	p53 suppresses carcinoma progression by inhibiting mTOR pathway activation.	Oncogene	2015 Jan 29	Akeno N	doi: 10.1038/onc.2013.589
27034171	Rheb may complex with RASSF1A to coordinate Hippo and TOR signaling.	Oncotarget	2016 Jun 7	Nelson N	doi: 10.18632/oncotarget.8447.
25110431	Aspirin inhibits cell viability and mTOR downstream signaling in gastroenteropancreatic and bronchopulmonary neuroendocrine tumor cells.	World J Gastroenterol	2014 Aug 7	Spampatti M	doi: 10.3748/wjg.v20.i29.10038.
26418749	Flcn-deficient renal cells are tumorigenic and sensitive to mTOR suppression.	Oncotarget	2015 Oct 20	Wu M	doi: 10.18632/oncotarget.5018.
25341684	SKLB-M8 induces apoptosis through the AKT/mTOR signaling pathway in melanoma models and inhibits angiogenesis with decrease of ERK1/2 phosphorylation.	J Pharmacol Sci	2014	Wang J	-
21383697	MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways.	Oncogene	2011 Aug 11	Oneyama C	doi: 10.1038/onc.2011.63
16929481	Carcinoma-associated eIF3i overexpression facilitates mTOR-dependent growth transformation.	Mol Carcinog	2006 Dec	Ahlemann M	-
26261591	Expression of phospho-mTOR kinase is abundant in colorectal cancer and associated with left-sided tumor localization.	Int J Clin Exp Pathol	2015 Jun 1	Melling N	-
19090006	Critical and diverse involvement of Akt/mammalian target of rapamycin signaling in human lung carcinomas.	Cancer	2009 Jan 1	Dobashi Y	doi: 10.1002/cncr.23996.
21859551	[Advances of LKB1-AMPK-mTOR Signaling Pathway in Tumor].	Zhongguo Fei Ai Za Zhi	2011 Aug	Zhang X	doi: 10.3779/j.issn.1009-3419.2011.08.09.
26722465	Phosphorylated mTOR expression correlates with podoplanin expression and high tumor grade in esophageal squamous cell carcinoma.	Int J Clin Exp Pathol	2015 Oct 1	Chuang WY	-
27226604	Mechanistic Target of Rapamycin (mTOR) Inhibition Synergizes with Reduced Internal Ribosome Entry Site (IRES)-mediated Translation of Cyclin D1 and c-MYC mRNAs to Treat Glioblastoma.	J Biol Chem	2016 Jul 1	Holmes B	doi: 10.1074/jbc.M116.726927
27012089	[REGULATION OF THE mTOR SIGNALING PATHWAY IN MACROPHAGES IN VARIOUS PATHOLOGIES].	Tsitologiia	2015	Zubova SG	-
25931349	Pro-Apoptotic Activity of Ruxolitinib Alone and in Combination with Hydroxyurea, Busulphan, and PI3K/mTOR Inhibitors in JAK2-Positive Human Cell Lines.	Adv Clin Exp Med	2015 Mar-Apr	Szyma??ska J	doi: 10.17219/acem/32934.
25862847	Targeting mTOR and AREG with everolimus, sunitinib and sorafenib in HPV-positive and -negative SCC.	Anticancer Res	2015 Apr	Aderhold C	-
19098000	The Akt/mTOR pathway assures the synthesis of HIF-1alpha protein in a glucose- and reoxygenation-dependent manner in irradiated tumors.	J Biol Chem	2009 Feb 20	Harada H	doi: 10.1074/jbc.M806653200
18926585	Role of TSC-mTOR pathway in diabetic nephropathy.	Diabetes Res Clin Pract	2008 Nov 13	Inoki K	doi: 10.1016/j.diabres.2008.09.028
25667121	The tumor-suppressor gene LZTS1 suppresses colorectal cancer proliferation through inhibition of the AKT-mTOR signaling pathway.	Cancer Lett	2015 Apr 28	Zhou W	doi: 10.1016/j.canlet.2015.02.004
25778319	Sorafenib inhibits liver cancer growth by decreasing mTOR, AKT, and PI3K expression.	J BUON	2015 Jan-Feb	Zhang CZ	-
26255626	Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.	Oncotarget	2015 Jul 20	Ghosh AP	-
19956179	Common corruption of the mTOR signaling network in human tumors.	Oncogene	2008 Dec	Menon S	doi: 10.1038/onc.2009.352.
22871496	Pharmacological targeting of mammalian target of rapamycin inhibits ovarian granulosa cell tumor growth.	Carcinogenesis	2012 Nov	Rico C	doi: 10.1093/carcin/bgs263
16912159	Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells.	Cancer Res	2006 Aug 15	Wang MY	-
28064317	[B7-H4-mediated immunoresistance is supressed by PI3K/Akt/mTOR pathway inhibitors].	Mol Biol (Mosk)	2016 Nov-Dec	Zeng S	doi: 10.7868/S0026898416060240.
19147764	Inhibition of mTOR radiosensitizes soft tissue sarcoma and tumor vasculature.	Clin Cancer Res	2009 Jan 15	Murphy JD	doi: 10.1158/1078-0432.CCR-08-1019.
23103253	HIF2α acts as an mTORC1 activator through the amino acid carrier SLC7A5.	Mol Cell	2012 Dec 14	Elorza A	doi: 10.1016/j.molcel.2012.09.017
26170313	Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance.	Proc Natl Acad Sci U S A	2015 Jul 28	Masui K	doi: 10.1073/pnas.1511759112
25807077	Tumor cells switch to mitochondrial oxidative phosphorylation under radiation via mTOR-mediated hexokinase II inhibition--a Warburg-reversing effect.	PLoS One	2015 Mar 25	Lu CL	doi: 10.1371/journal.pone.0121046
22944293	Clinicopathologic significance and function of mammalian target of rapamycin activation in esophageal squamous cell carcinoma.	Hum Pathol	2013 Feb	Kim SH	doi: 10.1016/j.humpath.2012.05.011
17148679	Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma.	Am J Pathol	2006 Dec	Peponi E	-
22287548	Macrophage-induced tumor angiogenesis is regulated by the TSC2-mTOR pathway.	Cancer Res	2012 Mar 15	Chen W	doi: 10.1158/0008-5472.CAN-11-2684
21837670	The Akt/mammalian target of rapamycin pathway is activated and associated with adverse prognosis in soft tissue leiomyosarcomas.	Cancer	2012 Mar 15	Setsu N	doi: 10.1002/cncr.26448
23963361	Novel treatment for mantle cell lymphoma including therapy-resistant tumor by NF-??B and mTOR dual-targeting approach.	Mol Cancer Ther	2013 Oct	Chaturvedi NK	doi: 10.1158/1535-7163.MCT-13-0239
26208432	mTOR inhibitors counteract tamoxifen-induced activation of breast cancer stem cells.	Cancer Lett	2015 Oct 10	Karthik GM	doi: 10.1016/j.canlet.2015.07.017
20668229	The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation.	Blood	2010 Nov 18	Green AS	doi: 10.1182/blood-2010-02-269837
23878245	Reactive nitrogen species regulate autophagy through ATM-AMPK-TSC2-mediated suppression of mTORC1.	Proc Natl Acad Sci U S A	2013 Aug 6	Tripathi DN	doi: 10.1073/pnas.1307736110
18650380	ATF6alpha-Rheb-mTOR signaling promotes survival of dormant tumor cells in vivo.	Proc Natl Acad Sci U S A	2008 Jul 29	Schewe DM	doi: 10.1073/pnas.0800939105
20048174	Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors.	J Clin Oncol	2010 Feb 10	Wagner AJ	doi: 10.1200/JCO.2009.25.2981
25854175	MicroRNA-199a-3p suppresses glioma cell proliferation by regulating the AKT/mTOR signaling pathway.	Tumour Biol	2015 Sep	Shen L	doi: 10.1007/s13277-015-3409-z
26993162	FGFR antagonist induces protective autophagy in FGFR1-amplified breast cancer cell.	Biochem Biophys Res Commun	2016 May 20	Chen Y	doi: 10.1016/j.bbrc.2016.03.017
28159681	The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL).	Cancer Lett	2017 Apr 28	Gazi M	doi: 10.1016/j.canlet.2017.01.035
27693556	Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.	Cancer Lett	2016 Dec 28	Muqbil I	doi: 10.1016/j.canlet.2016.09.016
28419191	PPAR?? promotes tumor progression via activation of Glut1 and SLC1-A5 transcription.	Carcinogenesis	2017 Jul 1	Zhang W	doi: 10.1093/carcin/bgx035.
27835987	Clinicopathological and prognostic significance of mTOR and phosphorylated mTOR expression in patients with esophageal squamous cell carcinoma: a systematic review and meta-analysis.	BMC Cancer	2016 Nov 11	Li S	-
28582508	Association of breast cancer risk and the mTOR pathway in women of African ancestry in 'The Root' Consortium.	Carcinogenesis	2017 Aug 1	Wang S	doi: 10.1093/carcin/bgx055.
28745319	The androgen receptor is a negative regulator of eIF4E phosphorylation at S209: implications for the use of mTOR inhibitors in advanced prostate cancer.	Oncogene	2017 Nov 16	D'Abronzo LS	doi: 10.1038/onc.2017.233
27147575	Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells.	Oncotarget	2016 May 31	Dong L	doi: 10.18632/oncotarget.9061.
27283897	Infiltrating macrophages increase RCC epithelial mesenchymal transition (EMT) and stem cell-like populations via AKT and mTOR signaling.	Oncotarget	2016 Jul 12	Yang Z	doi: 10.18632/oncotarget.9873.
27174915	IDO1 involvement in mTOR pathway: a molecular mechanism of resistance to mTOR targeting in medulloblastoma.	Oncotarget	2016 Aug 16	Folgiero V	doi: 10.18632/oncotarget.9284.
27285754	PI3K-PTEN dysregulation leads to mTOR-driven upregulation of the core clock gene BMAL1 in normal and malignant epithelial cells.	Oncotarget	2016 Jul 5	Matsumoto CS	doi: 10.18632/oncotarget.9877.
28002802	Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.	Oncotarget	2017 Jan 31	Fourneaux B	doi: 10.18632/oncotarget.13987.
28498460	MCM7 amplification and overexpression promote cell proliferation, colony formation and migration in esophageal squamous cell carcinoma by activating the AKT1/mTOR signaling pathway.	Oncol Rep	2017 Jun	Qiu YT	doi: 10.3892/or.2017.5614
28440461	The role of miR-451 in the switching between proliferation and migration in malignant glioma cells: AMPK signaling, mTOR modulation and Rac1 activation required.	Int J Oncol	2017 Jun	Zhao K	doi: 10.3892/ijo.2017.3973
28052030	The angiotensin II type 1 receptor antagonist telmisartan inhibits cell proliferation and tumor growth of esophageal adenocarcinoma via the AMPKα/mTOR pathway in vitro and in vivo.	Oncotarget	2017 Jan 31	Fujihara S	doi: 10.18632/oncotarget.14345.
29491094	mTORC1 and mTORC2 Expression Levels in Oral Squamous Cell Carcinoma: An Immunohistochemical and Clinicopathological Study.	Anticancer Res	2018 Mar	Kawasaki G	-
28468774	Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer.	Mol Cancer Ther	2017 Jul	Gordon MA	doi: 10.1158/1535-7163.MCT-17-0111
28007777	Noninvasive Measurement of mTORC1 Signaling with 89Zr-Transferrin.	Clin Cancer Res	2017 Jun 15	Truillet C	doi: 10.1158/1078-0432.CCR-16-2448
28624790	Co-targeting of IGF1R/mTOR pathway by miR-497 and miR-99a impairs hepatocellular carcinoma development.	Oncotarget	2017 Jul 18	Cheng H	doi: 10.18632/oncotarget.18207.
28791373	Downregulation of BZW2 inhibits osteosarcoma cell growth by inactivating the Akt/mTOR signaling pathway.	Oncol Rep	2017 Oct	Cheng DD	doi: 10.3892/or.2017.5890
29048631	Autophagy induction enhances tetrandrine-induced apoptosis via the AMPK/mTOR pathway in human bladder cancer cells.	Oncol Rep	2017 Nov	Kou B	doi: 10.3892/or.2017.5988
29448085	Plk2 Loss Commonly Occurs in Colorectal Carcinomas but not Adenomas: Relationship to mTOR Signaling.	Neoplasia	2018 Mar	Matthew EM	doi: 10.1016/j.neo.2018.01.004
30488209	Association of Target Therapy Gene Expression with Metastasizing of Clear-Cell Renal Cell Carcinoma.	Bull Exp Biol Med	2018 Dec	Apanovich NV	doi: 10.1007/s10517-018-4327-z
29403037	The mTOR-S6K pathway links growth signalling to DNA damage response by targeting RNF168.	Nat Cell Biol	2018 Mar	Xie X	doi: 10.1038/s41556-017-0033-8
18831768	TOR complex 2 is needed for cell cycle progression and anchorage-independent growth of MCF7 and PC3 tumor cells.	BMC Cancer	2008 Oct 3	Hietakangas V	doi: 10.1186/1471-2407-8-282.
20081105	A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer.	Mol Endocrinol	2010 Feb	Nagaraja AK	doi: 10.1210/me.2009-0295
23773481	Clinical impacts of mammalian target of rapamycin expression in human colorectal cancers.	Hum Pathol	2013 Oct	Alqurashi N	doi: 10.1016/j.humpath.2013.03.014
26097572	Expression and clinical significances of Beclin1, LC3 and mTOR in colorectal cancer.	Int J Clin Exp Pathol	2015 Apr 1	Wu S	-
24853425	SPAG5 upregulation predicts poor prognosis in cervical cancer patients and alters sensitivity to taxol treatment via the mTOR signaling pathway.	Cell Death Dis	2014 May 22	Yuan LJ	doi: 10.1038/cddis.2014.222.
25843797	DEPTOR-related mTOR suppression is involved in metformin's anti-cancer action in human liver cancer cells.	Biochem Biophys Res Commun	2015 May 15	Obara A	doi: 10.1016/j.bbrc.2015.03.148
25531318	LARP1 post-transcriptionally regulates mTOR and contributes to cancer progression.	Oncogene	2015 Sep 24	Mura M	doi: 10.1038/onc.2014.428
23246968	The evolution of the TOR pathway and its role in cancer.	Oncogene	2013 Aug 22	Beauchamp EM	doi: 10.1038/onc.2012.567
27315344	MicroRNA-224 aggrevates tumor growth and progression by targeting mTOR in gastric cancer.	Int J Oncol	2016 Sep	Zhang Y	doi: 10.3892/ijo.2016.3581
27109477	FXR blocks the growth of liver cancer cells through inhibiting mTOR-s6K pathway.	Biochem Biophys Res Commun	2016 May 27	Huang X	doi: 10.1016/j.bbrc.2016.04.106
28235484	Branched-chain amino acid transaminase 1 (BCAT1) promotes the growth of breast cancer cells through improving mTOR-mediated mitochondrial biogenesis and function.	Biochem Biophys Res Commun	2017 Apr 29	Zhang L	doi: 10.1016/j.bbrc.2017.02.101
28698135	MREG suppresses thyroid cancer cell invasion and proliferation by inhibiting Akt-mTOR signaling.	Biochem Biophys Res Commun	2017 Sep 9	Meng X	doi: 10.1016/j.bbrc.2017.07.044
27991928	Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition.	Oncogene	2017 May 11	Mateo F	doi: 10.1038/onc.2016.427
29307829	Blockage of cytosolic phospholipase A2 alpha sensitizes aggressive breast cancer to doxorubicin through suppressing ERK and mTOR kinases.	Biochem Biophys Res Commun	2018 Jan 29	Li Z	doi: 10.1016/j.bbrc.2018.01.016
27533457	Impacts of the mTOR gene polymorphisms rs2536 and rs2295080 on breast cancer risk in the Chinese population.	Oncotarget	2016 Sep 6	Zhao Y	doi: 10.18632/oncotarget.11272.
29978609	Synergistic Anti-Cancer Effects of AKT and SRC Inhibition in Human Pancreatic Cancer Cells.	Yonsei Med J	2018 Aug	Ahn K	doi: 10.3349/ymj.2018.59.6.727.
29749504	LSD1 negatively regulates autophagy through the mTOR signaling pathway in ovarian cancer cells.	Oncol Rep	2018 Jul	Wei Y	doi: 10.3892/or.2018.6432
30061533	mTOR and Tumor Cachexia.	Int J Mol Sci	2018 Jul 30	Duval AP	doi: 10.3390/ijms19082225.
30171261	mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer.	Oncogene	2019 Jan	Liang SQ	doi: 10.1038/s41388-018-0479-6
26287940	Genetic variations in the mTOR gene contribute toward gastric adenocarcinoma susceptibility in an Eastern Chinese population.	Pharmacogenet Genomics	2015 Nov	Wang MY	doi: 10.1097/FPC.0000000000000163.
26201060	The role of mTOR during cisplatin treatment in an in vitro and ex vivo model of cervical cancer.	Toxicology	2015 Sep 1	Leisching GR	doi: 10.1016/j.tox.2015.07.010
26311737	Licochalcone A induces autophagy through PI3K/Akt/mTOR inactivation and autophagy suppression enhances Licochalcone A-induced apoptosis of human cervical cancer cells.	Oncotarget	2015 Oct 6	Tsai JP	doi: 10.18632/oncotarget.4767.
23530221	Hypoxia induces a phase transition within a kinase signaling network in cancer cells.	Proc Natl Acad Sci U S A	2013 Apr 9	Wei W	doi: 10.1073/pnas.1303060110
26319900	Suppression of the GTPase-activating protein RGS10 increases Rheb-GTP and mTOR signaling in ovarian cancer cells.	Cancer Lett	2015 Dec 1	Altman MK	doi: 10.1016/j.canlet.2015.08.012
24556942	Limited significance of activated Akt-mammalian target of rapamycin signaling pathway in prostate cancer progression.	Urol Int	2014	Ko YH	doi: 10.1159/000356262
26427150	Inhibition of Autophagy Increases Proliferation Inhibition and Apoptosis Induced by the PI3K/mTOR Inhibitor NVP-BEZ235 in Breast Cancer Cells.	Clin Lab	2015	Ji Y	-
25421824	Wedelolactone inhibits breast cancer-induced osteoclastogenesis by decreasing Akt/mTOR signaling.	Int J Oncol	2015 Feb	Hsieh CJ	doi: 10.3892/ijo.2014.2769
19739122	Prognostic role of p-mTOR expression in cancer tissues and metastatic lymph nodes in pT2b gastric cancer.	Int J Cancer	2010 Jun 15	An JY	doi: 10.1002/ijc.24872.
20204306	RAD001 offers a therapeutic intervention through inhibition of mTOR as a potential strategy for esophageal cancer.	Oncol Rep	2010 Apr	Wang ZG	-
20354165	Energy balance, the PI3K-AKT-mTOR pathway genes, and the risk of bladder cancer.	Cancer Prev Res (Phila)	2010 Apr	Lin J	doi: 10.1158/1940-6207.CAPR-09-0263
26238185	MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1.	Oncotarget	2015 Sep 22	Xu S	doi: 10.18632/oncotarget.4762.
22127531	mTOR and PTEN expression in non-small cell lung cancer: analysis by real-time fluorescence quantitative polymerase chain reaction and immunohistochemistry.	Surg Today	2012 May	Wang L	doi: 10.1007/s00595-011-0028-1
25632222	Plumbagin induces cell cycle arrest and autophagy and suppresses epithelial to mesenchymal transition involving PI3K/Akt/mTOR-mediated pathway in human pancreatic cancer cells.	Drug Des Devel Ther	2015 Jan 17	Wang F	doi: 10.2147/DDDT.S73689
19553815	Promising molecular targets in ovarian cancer.	Curr Opin Oncol	2009 Sep	Blagden S	doi: 10.1097/CCO.0b013e32832eab1f.
25854169	Metformin inhibits thyroid cancer cell growth, migration, and EMT through the mTOR pathway.	Tumour Biol	2015 Aug	Han B	doi: 10.1007/s13277-015-3315-4
23832540	Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.	Tumour Biol	2013 Dec	Yothaisong S	doi: 10.1007/s13277-013-0945-2
27090655	Vascular endothelial growth factor A as predictive marker for mTOR inhibition in relapsing high-grade serous ovarian cancer.	BMC Syst Biol	2016 Apr 18	Andorfer P	doi: 10.1186/s12918-016-0278-z.
21276607	Activation of mTOR signaling pathway associated with adverse prognostic factors of epithelial ovarian cancer.	Gynecol Oncol	2011 Apr	No JH	doi: 10.1016/j.ygyno.2010.12.364
19164214	Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy.	J Clin Oncol	2009 Feb 20	Hildebrandt MA	doi: 10.1200/JCO.2008.17.6297
20019839	CCL2 is a negative regulator of AMP-activated protein kinase to sustain mTOR complex-1 activation, survivin expression, and cell survival in human prostate cancer PC3 cells.	Neoplasia	2009 Dec	Roca H	-
21177869	mTOR-dependent regulation of PHLPP expression controls the rapamycin sensitivity in cancer cells.	J Biol Chem	2011 Feb 25	Liu J	doi: 10.1074/jbc.M110.183087
18413763	A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis.	Cancer Res	2008 Apr 15	Shor B	doi: 10.1158/0008-5472.CAN-07-6487.
20153512	Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma.	Hum Pathol	2010 Jun	Bunkholt Elstrand M	doi: 10.1016/j.humpath.2009.09.017
20093977	Overexpression of the mammalian target of rapamycin: a novel biomarker for poor survival in resected early stage non-small cell lung cancer.	J Thorac Oncol	2010 Mar	Dhillon T	doi: 10.1097/JTO.0b013e3181ce6604.
23423739	Genetic variations of mTORC1 genes and risk of gastric cancer in an Eastern Chinese population.	Mol Carcinog	2013 Nov	He J	doi: 10.1002/mc.22013
25460505	DNA damage-induced S and G2/M cell cycle arrest requires mTORC2-dependent regulation of Chk1.	Oncotarget	2015 Jan 1	Selvarajah J	-
25632225	Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells.	Drug Des Devel Ther	2015 Jan 17	Wang F	doi: 10.2147/DDDT.S75221
19897009	The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors.	Mol Cell Endocrinol	2010 May 28	Saji M	doi: 10.1016/j.mce.2009.10.016
26577839	Genetic variants in the mTOR pathway and breast cancer risk in African American women.	Carcinogenesis	2016 Jan	Cheng TD	doi: 10.1093/carcin/bgv160
15802268	Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha.	J Biol Chem	2005 Jun 10	Phillips RJ	-
19949304	The role of mTOR in bladder cancer.	Cancer Biol Ther	2009 Dec	Gust KM	-
23940798	Polymorphisms in the mTOR gene and risk of sporadic prostate cancer in an Eastern Chinese population.	PLoS One	2013 Aug 5	Li Q	doi: 10.1371/journal.pone.0071968
25051360	Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.	Oncotarget	2014 Jul 15	Davis NM	-
27220494	MiR-21 modulates radiosensitivity of cervical cancer through inhibiting autophagy via the PTEN/Akt/HIF-1α feedback loop and the Akt-mTOR signaling pathway.	Tumour Biol	2016 Sep	Song L	-
25108739	Association between germline single nucleotide polymorphisms in the PI3K-AKT-mTOR pathway, obesity, and breast cancer disease-free survival.	Breast Cancer Res Treat	2014 Sep	Pande M	doi: 10.1007/s10549-014-3081-9
25043667	Expression of phosphorylated-mTOR during the development of prostate cancer.	Prostate	2014 Sep	Sutherland SI	doi: 10.1002/pros.22840
18702307	[Role of PTEN protein in multidrug resistance of prostate cancer cells].	Mol Biol (Mosk)	2008 May-Jun	Sherbakova EA	-
23886172	Prognostic value of phosphorylated mTOR/RPS6KB1 in non- small cell lung cancer.	Asian Pac J Cancer Prev	2013	Zhang Y	-
23623586	Relevance of the mammalian target of rapamycin pathway in the prognosis of patients with high-risk non-muscle invasive bladder cancer.	Hum Pathol	2013 Sep	Fahmy M	doi: 10.1016/j.humpath.2012.11.026
17409838	Targeting mTOR signaling for lung cancer therapy.	J Thorac Oncol	2006 Feb	Sun SY	-
12813467	Phospholipase D confers rapamycin resistance in human breast cancer cells.	Oncogene	2003 Jun 19	Chen Y	-
18570873	mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation.	Mol Cell	2008 Jun 20	Hong F	doi: 10.1016/j.molcel.2008.04.027.
23322780	Mutations in critical domains confer the human mTOR gene strong tumorigenicity.	J Biol Chem	2013 Mar 1	Murugan AK	doi: 10.1074/jbc.M112.399485
27055253	Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer.	PLoS One	2016 Apr 7	Cardnell RJ	doi: 10.1371/journal.pone.0152584
20727662	Clinical significance of pmTOR expression in endometrioid endometrial carcinoma.	Eur J Obstet Gynecol Reprod Biol	2010 Dec	Choi CH	doi: 10.1016/j.ejogrb.2010.07.038
17616691	AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway.	Cancer Res	2007 Jul 1	Liu LZ	-
18622747	Mammalian target of rapamycin pathway inhibition enhances the effects of 5-aza-dC on suppressing cell proliferation in human gastric cancer cell lines.	Sci China C Life Sci	2008 Jul	Sun D	doi: 10.1007/s11427-008-0080-2
26158266	Inhibition of Aerobic Glycolysis Represses Akt/mTOR/HIF-1α Axis and Restores Tamoxifen Sensitivity in Antiestrogen-Resistant Breast Cancer Cells.	PLoS One	2015 Jul 9	Woo YM	doi: 10.1371/journal.pone.0132285
22367541	The translational landscape of mTOR signalling steers cancer initiation and metastasis.	Nature	2012 Feb 22	Hsieh AC	doi: 10.1038/nature10912.
20805015	Phospholipase D-mTOR requirement for the Warburg effect in human cancer cells.	Cancer Lett	2010 Dec 18	Toschi A	doi: 10.1016/j.canlet.2010.08.006.
20630061	Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies.	BMC Cancer	2010 Jul 14	Javle MM	doi: 10.1186/1471-2407-10-368.
25735853	A liaison between mTOR signaling, ribosome biogenesis and cancer.	Biochim Biophys Acta	2015 Jul	Gentilella A	doi: 10.1016/j.bbagrm.2015.02.005
26639561	BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer.	Sci Rep	2015 Dec 7	Karachaliou N	doi: 10.1038/srep17499.
19624311	GOLPH3 links the Golgi network to mTOR signaling and human cancer.	Pigment Cell Melanoma Res	2009 Aug	Abraham RT	doi: 10.1111/j.1755-148X.2009.00596.x.
22684558	Suppression of EphB4 improves the inhibitory effect of mTOR shRNA on the biological behaviors of ovarian cancer cells by down-regulating Akt phosphorylation.	J Huazhong Univ Sci Technolog Med Sci	2012 Jun	Ma X	doi: 10.1007/s11596-012-0062-2
25659153	Tanshinone IIA inhibits HIF-1α and VEGF expression in breast cancer cells via mTOR/p70S6K/RPS6/4E-BP1 signaling pathway.	PLoS One	2015 Feb 6	Li G	doi: 10.1371/journal.pone.0117440
19020722	Activation of mTOR in a subgroup of ovarian carcinomas: correlation with p-eIF-4E and prognosis.	Oncol Rep	2008 Dec	Noske A	-
21372221	Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma.	Clin Cancer Res	2011 Apr 15	Santiskulvong C	doi: 10.1158/1078-0432.CCR-10-2289
24334141	mTOR-dependent transcriptional repression of Pdcd4 tumor suppressor in lung cancer cells.	Biochim Biophys Acta	2014 Jan	Vikhreva PN	doi: 10.1016/j.bbagrm.2013.12.001
26823699	Oleanolic acid suppresses the proliferation of human bladder cancer by Akt/mTOR/S6K and ERK1/2 signaling.	Int J Clin Exp Pathol	2015 Nov 1	Mu DW	-
22983984	Downregulation of miR-144 is associated with colorectal cancer progression via activation of mTOR signaling pathway.	Carcinogenesis	2012 Dec	Iwaya T	doi: 10.1093/carcin/bgs288
24695460	Downregulation of mTOR by lentivirus inhibits prostate cancer cell growth.	Int J Clin Exp Pathol	2014 Feb 15	Du YF	-
26160839	Halofuginone inhibits colorectal cancer growth through suppression of Akt/mTORC1 signaling and glucose metabolism.	Oncotarget	2015 Sep 15	Chen GQ	-
22029423	Resveratrol enhances prostate cancer cell response to ionizing radiation. Modulation of the AMPK, Akt and mTOR pathways.	Radiat Oncol	2011 Oct 26	Rashid A	doi: 10.1186/1748-717X-6-144.
24571487	Inhibition of mTORC1 induces loss of E-cadherin through AKT/GSK-3β signaling-mediated upregulation of E-cadherin repressor complexes in non-small cell lung cancer cells.	Respir Res	2014 Feb 26	Kim EY	doi: 10.1186/1465-9921-15-26.
24816861	Association of mTOR polymorphisms with cancer risk and clinical outcomes: a meta-analysis.	PLoS One	2014 May 9	Shao J	doi: 10.1371/journal.pone.0097085
23841076	The omega-3 polyunsaturated fatty acid DHA induces simultaneous apoptosis and autophagy via mitochondrial ROS-mediated Akt-mTOR signaling in prostate cancer cells expressing mutant p53.	Biomed Res Int	2013	Shin S	doi: 10.1155/2013/568671
17693255	IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway.	Cell	2007 Aug 10	Lee DF	-
19223902	Relation between outcomes and localisation of p-mTOR expression in gastric cancer.	Br J Cancer	2009 Mar 10	Murayama T	doi: 10.1038/sj.bjc.6604915
18776922	Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival.	Oncogene	2008 Nov 27	Wang Y	doi: 10.1038/onc.2008.318
20479250	PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer.	Proc Natl Acad Sci U S A	2010 Jun 1	Loi S	doi: 10.1073/pnas.0907011107
25600244	Activation of mTOR/S6K But Not MAPK Pathways Might Be Associated With High Ki-67, ER(+), and HER2(-) Breast Cancer.	Clin Breast Cancer	2015 Jun	Yanai A	doi: 10.1016/j.clbc.2014.12.002
21277936	Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors.	Exp Hematol	2011 Apr	Batista A	doi: 10.1016/j.exphem.2011.01.005
24624456	PTEN/PI3K/mTOR/B7-H1 signaling pathway regulates cell progression and immuno-resistance in pancreatic cancer.	Hepatogastroenterology	2013 Oct	Zhang Y	-
22471665	Targeting PI3 kinase/AKT/mTOR signaling in cancer.	Crit Rev Oncog	2012	Sheppard K	-
20061787	Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer.	Cancer Biol Ther	2009 Dec	Mansure JJ	-
25029414	Switch in signaling control of mTORC1 activity after oncoprotein expression in thyroid cancer cell lines.	J Clin Endocrinol Metab	2014 Oct	Malaguarnera R	doi: 10.1210/jc.2013-3976
26012635	HER2-mTOR signaling-driven breast cancer cells require ER-associated degradation to survive.	Sci Signal	2015 May 26	Singh N	doi: 10.1126/scisignal.aaa6922.
26267321	The PI3K/AKT/mTOR pathway is a potential predictor of distinct invasive and migratory capacities in human ovarian cancer cell lines.	Oncotarget	2015 Sep 22	Bai H	doi: 10.18632/oncotarget.4550.
26652716	MMP2 and MMP7 at the invasive front of gastric cancer are not associated with mTOR expression.	Diagn Pathol	2015 Dec 12	Bornschein J	doi: 10.1186/s13000-015-0449-z.
26339598	Docosahexaenoic Acid Induces Cell Death in Human Non-Small Cell Lung Cancer Cells by Repressing mTOR via AMPK Activation and PI3K/Akt Inhibition.	Biomed Res Int	2015	Kim N	doi: 10.1155/2015/239764
23555892	A polymorphism (rs2295080) in mTOR promoter region and its association with gastric cancer in a Chinese population.	PLoS One	2013	Xu M	doi: 10.1371/journal.pone.0060080
26235873	Inactivated Sendai virus induces apoptosis and autophagy via the PI3K/Akt/mTOR/p70S6K pathway in human non-small cell lung cancer cells.	Biochem Biophys Res Commun	2015 Sep 11	Zhang Q	doi: 10.1016/j.bbrc.2015.07.130
23933173	mTOR activation in immature cells of primary nasopharyngeal carcinoma and anti-tumor effect of rapamycin in vitro and in vivo.	Cancer Lett	2013 Dec 1	Yang C	doi: 10.1016/j.canlet.2013.08.004
21325052	Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth.	Proc Natl Acad Sci U S A	2011 Mar 8	Sun Q	doi: 10.1073/pnas.1014769108
24637915	MiR-99a antitumor activity in human breast cancer cells through targeting of mTOR expression.	PLoS One	2014 Mar 17	Hu Y	doi: 10.1371/journal.pone.0092099
15028555	G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.	Am J Physiol Cell Physiol	2004 Aug	Gao N	-
26432419	Transforming somatic mutations of mammalian target of rapamycin kinase in human cancer.	Cancer Sci	2015 Dec	Yamaguchi H	doi: 10.1111/cas.12828
21412012	Clinical significance of genetic variations in the PI3K/PTEN/AKT/mTOR pathway in Korean patients with colorectal cancer.	Oncology	2010	Kim JG	doi: 10.1159/000320761
26744318	MicroRNA 100 sensitizes luminal A breast cancer cells to paclitaxel treatment in part by targeting mTOR.	Oncotarget	2016 Feb 2	Zhang B	doi: 10.18632/oncotarget.6790.
24011934	Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.	Eur J Cancer	2013 Dec	Sheppard KE	doi: 10.1016/j.ejca.2013.08.007
25816324	Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.	PLoS One	2015 Mar 27	Deng L	doi: 10.1371/journal.pone.0120511
26585486	Activation of mTORC1 under nutrient starvation conditions increases cellular radiosensitivity in human liver cancer cell lines, HepG2 and HuH6.	Biochem Biophys Res Commun	2015 Dec 25	Murata Y	doi: 10.1016/j.bbrc.2015.11.016
24027431	TBK1 regulates prostate cancer dormancy through mTOR inhibition.	Neoplasia	2013 Sep	Kim JK	-
18395956	Elevated phosphatidylinositol 3-kinase activation and its clinicopathological significance in cervical cancer.	Eur J Obstet Gynecol Reprod Biol	2008 Aug	Zhang XY	doi: 10.1016/j.ejogrb.2007.12.021
25918246	mTOR Complex 2 Stabilizes Mcl-1 Protein by Suppressing Its Glycogen Synthase Kinase 3-Dependent and SCF-FBXW7-Mediated Degradation.	Mol Cell Biol	2015 Jul	Koo J	doi: 10.1128/MCB.01525-14
20811725	2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways.	Int J Oncol	2010 Oct	Li CM	-
26935715	Anti-proliferative effect of RCE-4 from Reineckia carnea on human cervical cancer HeLa cells by inhibiting the PI3K/Akt/mTOR signaling pathway and NF-??B activation.	Naunyn Schmiedebergs Arch Pharmacol	2016 Jun	Bai C	doi: 10.1007/s00210-016-1217-7
23178462	Negative regulation of mTOR activity by LKB1-AMPK signaling in non-small cell lung cancer cells.	Acta Pharmacol Sin	2013 Feb	Dong LX	doi: 10.1038/aps.2012.143
20459645	Osteopontin selectively regulates p70S6K/mTOR phosphorylation leading to NF-kappaB dependent AP-1-mediated ICAM-1 expression in breast cancer cells.	Mol Cancer	2010 May 7	Ahmed M	doi: 10.1186/1476-4598-9-101.
19020730	TAE226, a dual inhibitor for FAK and IGF-IR, has inhibitory effects on mTOR signaling in esophageal cancer cells.	Oncol Rep	2008 Dec	Wang ZG	-
24630930	Catalase expression in MCF-7 breast cancer cells is mainly controlled by PI3K/Akt/mTor signaling pathway.	Biochem Pharmacol	2014 May 15	Glorieux C	doi: 10.1016/j.bcp.2014.02.025
25749387	The miR-491-3p/mTORC2/FOXO1 regulatory loop modulates chemo-sensitivity in human tongue cancer.	Oncotarget	2015 Mar 30	Zheng G	-
18612547	Formation of tissue factor-factor VIIa-factor Xa complex induces activation of the mTOR pathway which regulates migration of human breast cancer cells.	Thromb Haemost	2008 Jul	Jiang X	doi: 10.1160/TH07-12-0722.
21339740	Selective activation of Akt1 by mammalian target of rapamycin complex 2 regulates cancer cell migration, invasion, and metastasis.	Oncogene	2011 Jun 30	Kim EK	doi: 10.1038/onc.2011.22
26780727	Mefloquine effectively targets gastric cancer cells through phosphatase-dependent inhibition of PI3K/Akt/mTOR signaling pathway.	Biochem Biophys Res Commun	2016 Feb 5	Liu Y	doi: 10.1016/j.bbrc.2016.01.046
22457328	.	Sci Signal	2012 Mar 27	Fingar DC	doi: 10.1126/scisignal.2003026.
22349822	Critical role of arachidonic acid-activated mTOR signaling in breast carcinogenesis and angiogenesis.	Oncogene	2013 Jan 10	Wen ZH	doi: 10.1038/onc.2012.47
22452883	Inhibition of mTORC1 kinase activates Smads 1 and 5 but not Smad8 in human prostate cancer cells, mediating cytostatic response to rapamycin.	Mol Cancer Res	2012 Jun	Wahdan-Alaswad RS	doi: 10.1158/1541-7786.MCR-11-0615
21886838	Calcineurin inhibitor-induced and Ras-mediated overexpression of VEGF in renal cancer cells involves mTOR through the regulation of PRAS40.	PLoS One	2011	Basu A	doi: 10.1371/journal.pone.0023919
23991038	Luminal breast cancer cell lines overexpressing ZNF703 are resistant to tamoxifen through activation of Akt/mTOR signaling.	PLoS One	2013 Aug 26	Zhang X	doi: 10.1371/journal.pone.0072053
17911267	Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance.	Proc Natl Acad Sci U S A	2007 Oct 9	Zhou J	-
18848473	The TSC-mTOR signaling pathway regulates the innate inflammatory response.	Immunity	2008 Oct 17	Weichhart T	doi: 10.1016/j.immuni.2008.08.012
23297825	Targeting the mTOR pathway in tumor malignancy.	Curr Cancer Drug Targets	2013 Mar	Cheng H	-
16341243	Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.	Nat Med	2006 Jan	Thomas GV	-
21035497	Deciphering the signaling pathways of cancer stem cells of glioblastoma multiforme: role of Akt/mTOR and MAPK pathways.	Adv Enzyme Regul	2011	Jhanwar-Uniyal M	doi: 10.1016/j.advenzreg.2010.09.017
24631838	A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.	Cancer Discov	2014 May	Grabiner BC	doi: 10.1158/2159-8290.CD-13-0929
25128827	PGE2-induced colon cancer growth is mediated by mTORC1.	Biochem Biophys Res Commun	2014 Sep 5	Dufour M	doi: 10.1016/j.bbrc.2014.08.032
19875696	Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk.	Carcinogenesis	2009 Dec	Chen M	doi: 10.1093/carcin/bgp258.
26427711	Anticancer effect of rapamycin on MCF-7 via downregulation of VEGF expression.	In Vitro Cell Dev Biol Anim	2016 Jan	Fujii T	doi: 10.1007/s11626-015-9944-5
20145209	ARD1 stabilization of TSC2 suppresses tumorigenesis through the mTOR signaling pathway.	Sci Signal	2010 Feb 9	Kuo HP	doi: 10.1126/scisignal.2000590.
21046231	The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells.	Breast Cancer Res Treat	2011 Sep	Br??nner-Kubath C	doi: 10.1007/s10549-010-1232-1
26284586	mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib.	Oncotarget	2015 Nov 24	Hanly EK	doi: 10.18632/oncotarget.4052.
19223493	Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer.	Clin Cancer Res	2009 Mar 1	Yu G	doi: 10.1158/1078-0432.CCR-08-2138
22815832	Genetic variations in a PTEN/AKT/mTOR axis and prostate cancer risk in a Chinese population.	PLoS One	2012	Chen J	doi: 10.1371/journal.pone.0040817
20929525	Activated mammalian target of rapamycin is a potential therapeutic target in gastric cancer.	BMC Cancer	2010 Oct 7	Xu DZ	doi: 10.1186/1471-2407-10-536.
16786123	Predictive and prognostic role of activated mammalian target of rapamycin in cervical cancer treated with cisplatin-based neoadjuvant chemotherapy.	Oncol Rep	2006 Jul	Faried LS	-
22340595	Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells.	Cancer Cell	2012 Feb 14	Muranen T	doi: 10.1016/j.ccr.2011.12.024.
17631500	Up-regulation of acetyl-CoA carboxylase alpha and fatty acid synthase by human epidermal growth factor receptor 2 at the translational level in breast cancer cells.	J Biol Chem	2007 Sep 7	Yoon S	-
26617795	TMP21 modulates cell growth in papillary thyroid cancer cells by inducing autophagy through activation of the AMPK/mTOR pathway.	Int J Clin Exp Pathol	2015 Sep 1	Xu X	-
27796683	Akt/AMPK/mTOR pathway was involved in the autophagy induced by vitamin E succinate in human gastric cancer SGC-7901 cells.	Mol Cell Biochem	2017 Jan	Yu Y	doi: 10.1007/s11010-016-2853-4
26753650	Expression of mTOR and its inhibitory effect on cell proliferation and apoptosis of breast cancer cells.	J Biol Regul Homeost Agents	2015 Oct-Dec	Cheng XF	-
19553991	GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer.	Nature	2009 Jun 25	Scott KL	doi: 10.1038/nature08109.
24508774	Targeting bone metastatic cancer: Role of the mTOR pathway.	Biochim Biophys Acta	2014 Apr	Bertoldo F	doi: 10.1016/j.bbcan.2014.01.009
16652388	Expression of mTOR signaling pathway markers in prostate cancer progression.	Prostate	2006 Aug 1	Kremer CL	-
22399812	TGF-β-induced activation of mTOR complex 2 drives epithelial-mesenchymal transition and cell invasion.	J Cell Sci	2012 Mar 1	Lamouille S	doi: 10.1242/jcs.095299
18519641	Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK.	Genes Dev	2008 Jun 1	Dan HC	doi: 10.1101/gad.1662308.
17545512	The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy.	Clin Cancer Res	2007 Jun 1	Abraham RT	-
26499488	Puquitinib mesylate (XC-302) induces autophagy via inhibiting the PI3K/AKT/mTOR signaling pathway in nasopharyngeal cancer cells.	Int J Mol Med	2015 Dec	Wang KF	doi: 10.3892/ijmm.2015.2378
15580312	Alternative phospholipase D/mTOR survival signal in human breast cancer cells.	Oncogene	2005 Jan 20	Chen Y	-
27572296	RLIP76 increases apoptosis through Akt/mTOR signaling pathway in gastric cancer.	Oncol Rep	2016 Oct	Wang W	doi: 10.3892/or.2016.5043
25729885	Small molecule schweinfurthins selectively inhibit cancer cell proliferation and mTOR/AKT signaling by interfering with trans-Golgi-network trafficking.	Cancer Biol Ther	2015	Bao X	doi: 10.1080/15384047.2015.1019184
20190810	Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer.	Oncogene	2010 May 6	Sato T	doi: 10.1038/onc.2010.28
12242281	Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.	Mol Cell Biol	2002 Oct	Hudson CC	-
23828865	Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells.	Endocr Relat Cancer	2013 Aug 21	Gild ML	doi: 10.1530/ERC-13-0085
23886294	miR-99b-targeted mTOR induction contributes to irradiation resistance in pancreatic cancer.	Mol Cancer	2013 Jul 25	Wei F	doi: 10.1186/1476-4598-12-81.
24991762	CXCR4 and CXCR7 transduce through mTOR in human renal cancer cells.	Cell Death Dis	2014 Jul 3	Ieran?? C	doi: 10.1038/cddis.2014.269.
21373201	Genetic variability of the mTOR pathway and prostate cancer risk in the European Prospective Investigation on Cancer (EPIC).	PLoS One	2011 Feb 23	Campa D	doi: 10.1371/journal.pone.0016914.
20811722	Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status.	Int J Oncol	2010 Oct	Nagata Y	-
18652687	Deciphering downstream gene targets of PI3K/mTOR/p70S6K pathway in breast cancer.	BMC Genomics	2008 Jul 24	Heinonen H	doi: 10.1186/1471-2164-9-348.
21170086	Genome-wide shRNA screen reveals increased mitochondrial dependence upon mTORC2 addiction.	Oncogene	2011 Mar 31	Colombi M	doi: 10.1038/onc.2010.539
26367112	MiR-634 decreases cell proliferation and induces apoptosis by targeting mTOR signaling pathway in cervical cancer cells.	Artif Cells Nanomed Biotechnol	2016 Nov	Cong J	doi: 10.3109/21691401.2015.1080171
24668416	miR-99a and -99b inhibit cervical cancer cell proliferation and invasion by targeting mTOR signaling pathway.	Med Oncol	2014 May	Wang L	doi: 10.1007/s12032-014-0934-3
22685542	microRNA-21 governs TORC1 activation in renal cancer cell proliferation and invasion.	PLoS One	2012	Dey N	doi: 10.1371/journal.pone.0037366
17616684	Regulation of mammalian target of rapamycin activity in PTEN-inactive prostate cancer cells by I kappa B kinase alpha.	Cancer Res	2007 Jul 1	Dan HC	-
18787170	FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.	Science	2008 Sep 12	Mao JH	doi: 10.1126/science.1162981.
22952422	Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer.	Neoplasia	2012 Aug	Weekes CD	-
27959445	Delphinidin inhibits angiogenesis through the suppression of HIF-1α and VEGF expression in A549 lung cancer cells.	Oncol Rep	2017 Feb	Kim MH	doi: 10.3892/or.2016.5296
28408137	4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway.	Toxicol Appl Pharmacol	2017 Jun 15	Liu M	doi: 10.1016/j.taap.2017.04.003
27211906	Differential effects of rapalogues, dual kinase inhibitors on human ovarian carcinoma cells in vitro.	Int J Oncol	2016 Jul	Rogers-Broadway KR	doi: 10.3892/ijo.2016.3531
27996156	α-enolase promotes tumorigenesis and metastasis via regulating AMPK/mTOR pathway in colorectal cancer.	Mol Carcinog	2017 May	Zhan P	doi: 10.1002/mc.22603
27301639	PI3K/Akt/mTOR activation by suppression of ELK3 mediates chemosensitivity of MDA-MB-231 cells to doxorubicin by inhibiting autophagy.	Biochem Biophys Res Commun	2016 Aug 19	Park JH	doi: 10.1016/j.bbrc.2016.06.057
28639903	Targeting the mTOR pathway in breast cancer.	Tumour Biol	2017 Jun	Liu J	doi: 10.1177/1010428317710825.
28005970	Phosphorylated Mammalian Target of Rapamycin p-mTOR Is a Favorable Prognostic Factor than mTOR in Gastric Cancer.	PLoS One	2016 Dec 22	Cao GD	doi: 10.1371/journal.pone.0168085
27746162	Diminished DYRK2 sensitizes hormone receptor-positive breast cancer to everolimus by the escape from degrading mTOR.	Cancer Lett	2017 Jan 1	Mimoto R	doi: 10.1016/j.canlet.2016.10.015
27385486	Mutant p53 and mTOR/PKM2 regulation in cancer cells.	IUBMB Life	2016 Sep	Dando I	doi: 10.1002/iub.1534
26876207	Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapies.	Oncogene	2016 Sep 1	Zhou J	doi: 10.1038/onc.2016.4
28574664	Chemokine (CC motif) ligand 18 upregulates Slug expression to promote stem-cell like features by activating the mammalian target of rapamycin pathway in oral squamous cell carcinoma.	Cancer Sci	2017 Aug	Wang H	doi: 10.1111/cas.13289
28870807	A natural product toosendanin inhibits epithelial-mesenchymal transition and tumor growth in pancreatic cancer via deactivating Akt/mTOR signaling.	Biochem Biophys Res Commun	2017 Nov 4	Pei Z	doi: 10.1016/j.bbrc.2017.08.170
28716898	TBK1 Provides Context-Selective Support of the Activated AKT/mTOR Pathway in Lung Cancer.	Cancer Res	2017 Sep 15	Cooper JM	doi: 10.1158/0008-5472.CAN-17-0829
28923857	MetaLnc9 Facilitates Lung Cancer Metastasis via a PGK1-Activated AKT/mTOR Pathway.	Cancer Res	2017 Nov 1	Yu T	doi: 10.1158/0008-5472.CAN-17-0671
27036037	Age related increase in mTOR activity contributes to the pathological changes in ovarian surface epithelium.	Oncotarget	2016 Apr 12	Bajwa P	doi: 10.18632/oncotarget.8468.
26895472	mTOR inhibitors, a new era for metastatic luminal HER2-negative breast cancer? A systematic review and a meta-analysis of randomized trials.	Oncotarget	2016 May 10	Rotundo MS	doi: 10.18632/oncotarget.7446.
29103666	Identification of single nucleotide polymorphisms of the PI3K-AKT-mTOR pathway as a risk factor of central nervous system metastasis in metastatic breast cancer.	Eur J Cancer	2017 Dec	Le Rhun E	doi: 10.1016/j.ejca.2017.10.006
27009856	mTOR regulates proteasomal degradation and Dp1/E2F1- mediated transcription of KPNA2 in lung cancer cells.	Oncotarget	2016 May 3	Wang CI	doi: 10.18632/oncotarget.8170.
27150059	Nesfatin-1/Nucleobindin-2 enhances cell migration, invasion, and epithelial-mesenchymal transition via LKB1/AMPK/TORC1/ZEB1 pathways in colon cancer.	Oncotarget	2016 May 24	Kan JY	doi: 10.18632/oncotarget.9140.
27096957	mTOR pathway activation is a favorable prognostic factor in human prostate adenocarcinoma.	Oncotarget	2016 May 31	Stelloo S	doi: 10.18632/oncotarget.8767.
27853903	Does any drug to treat cancer target mTOR and iron hemostasis in neurodegenerative disorders?	Biometals	2017 Feb	Jodeiri Farshbaf M	doi: 10.1007/s10534-016-9981-x
27015560	mTOR complex-2 stimulates acetyl-CoA and de novo lipogenesis through ATP citrate lyase in HER2/PIK3CA-hyperactive breast cancer.	Oncotarget	2016 May 3	Chen Y	doi: 10.18632/oncotarget.8279.
28741507	mTOR Signaling Confers Resistance to Targeted Cancer Drugs.	Trends Cancer	2016 Nov	Guri Y	doi: 10.1016/j.trecan.2016.10.006
29185784	miR-21 Inhibitors Modulate Biological Functions of Gastric Cancer Cells via PTEN/PI3K/mTOR Pathway.	DNA Cell Biol	2018 Jan	Wang P	doi: 10.1089/dna.2017.3922
27462867	Genetic polymorphisms of mTOR and cancer risk: a systematic review and updated meta-analysis.	Oncotarget	2016 Aug 30	Zining J	doi: 10.18632/oncotarget.10805.
27517315	Growth factor progranulin promotes tumorigenesis of cervical cancer via PI3K/Akt/mTOR signaling pathway.	Oncotarget	2016 Sep 6	Feng T	doi: 10.18632/oncotarget.11126.
27974704	MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling.	Oncotarget	2017 Jan 31	Offermann A	doi: 10.18632/oncotarget.13860.
27472392	Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation.	Oncotarget	2016 Sep 6	Henry RE	doi: 10.18632/oncotarget.10859.
27863387	Aberrant overexpression of ADAR1 promotes gastric cancer progression by activating mTOR/p70S6K signaling.	Oncotarget	2016 Dec 27	Dou N	doi: 10.18632/oncotarget.13354.
28427795	Reappraisal to the study of 4E-BP1 as an mTOR substrate - A normative critique.	Eur J Cell Biol	2017 Jun	Batool A	doi: 10.1016/j.ejcb.2017.03.013
28569781	Mitochondrial AKAP1 supports mTOR pathway and tumor growth.	Cell Death Dis	2017 Jun 1	Rinaldi L	doi: 10.1038/cddis.2017.241.
28661070	microRNA-145-3p inhibits non-small cell lung cancer cell migration and invasion by targeting PDK1 via the mTOR signaling pathway.	J Cell Biochem	2018 Jan	Chen GM	doi: 10.1002/jcb.26252
28899863	A Unified Approach to Targeting the Lysosome's Degradative and Growth Signaling Roles.	Cancer Discov	2017 Nov	Rebecca VW	doi: 10.1158/2159-8290.CD-17-0741
29081412	MiR-101 reduces cell proliferation and invasion and enhances apoptosis in endometrial cancer via regulating PI3K/Akt/mTOR.	Cancer Biomark	2017 Dec 12	Zhang S	doi: 10.3233/CBM-170620.
29393469	TRIM28 promotes cervical cancer growth through the mTOR signaling pathway.	Oncol Rep	2018 Apr	Li F	doi: 10.3892/or.2018.6235
29484437	miR-181 regulates cisplatin-resistant non-small cell lung cancer via downregulation of autophagy through the PTEN/PI3K/AKT pathway.	Oncol Rep	2018 Apr	Liu J	doi: 10.3892/or.2018.6268
28724614	Nuclear mTOR acts as a transcriptional integrator of the androgen signaling pathway in prostate cancer.	Genes Dev	2017 Jun 15	Audet-Walsh ??	doi: 10.1101/gad.299958.117
29328491	MicroRNA-let-7a regulates cell autophagy by targeting Rictor in gastric cancer cell lines MGC-803 and SGC-7901.	Oncol Rep	2018 Mar	Fan H	doi: 10.3892/or.2018.6194
29488612	Piperine depresses the migration progression via downregulating the Akt/mTOR/MMP9 signaling pathway in DU145 cells.	Mol Med Rep	2018 May	Zeng Y	doi: 10.3892/mmr.2018.8653
29807226	MiR-206 inhibits epithelial ovarian cancer cells growth and invasion via blocking c-Met/AKT/mTOR signaling pathway.	Biomed Pharmacother	2018 Aug	Dai C	doi: 10.1016/j.biopha.2018.05.077
29086897	Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer.	Breast Cancer	2018 Jul	Araki K	doi: 10.1007/s12282-017-0812-x
29568966	PPP2R2D, a regulatory subunit of protein phosphatase2A, promotes gastric cancer growth and metastasis via mechanistic target of rapamycin activation.	Int J Oncol	2018 Jun	Yu S	doi: 10.3892/ijo.2018.4329
29566977	CO suppresses prostate cancer cell growth by directly targeting LKB1/AMPK/mTOR pathway in vitro and in vivo.	Urol Oncol	2018 Jun	Yan Y	doi: 10.1016/j.urolonc.2018.02.013
28332630	PML nuclear bodies contribute to the basal expression of the mTOR inhibitor DDIT4.	Sci Rep	2017 Mar 23	Salsman J	doi: 10.1038/srep45038.
29862445	Expression of miRNAs Targeting mTOR and S6K1 Genes of mTOR Signaling Pathway Including miR-96, miR-557, and miR-3182 in Triple-Negative Breast Cancer.	Appl Biochem Biotechnol	2018 Dec	Razaviyan J	doi: 10.1007/s12010-018-2773-8
30272366	Clinical associations between ASCT2 and pmTOR in the pathogenesis and prognosis of epithelial ovarian cancer.	Oncol Rep	2018 Dec	Guo H	doi: 10.3892/or.2018.6729
28484242	Regulation of CHK1 by mTOR contributes to the evasion of DNA damage barrier of cancer cells.	Sci Rep	2017 May 8	Zhou X	doi: 10.1038/s41598-017-01729-w.
30226616	C16ceramide and sphingosine1phosphate/S1PR2 have opposite effects on cell growth through mTOR signaling pathway regulation.	Oncol Rep	2018 Nov	Kim MH	doi: 10.3892/or.2018.6689
29449346	Shikonin suppresses proliferation and induces apoptosis in endometrioid endometrial cancer cells via modulating miR-106b/PTEN/AKT/mTOR signaling pathway.	Biosci Rep	2018 Apr 13	Huang C	doi: 10.1042/BSR20171546
29133593	Adipose-Derived VEGF-mTOR Signaling Promotes Endometrial Hyperplasia and Cancer: Implications for Obese Women.	Mol Cancer Res	2018 Feb	Sahoo SS	doi: 10.1158/1541-7786.MCR-17-0466
30419950	LAT2 regulates glutamine-dependent mTOR activation to promote glycolysis and chemoresistance in pancreatic cancer.	J Exp Clin Cancer Res	2018 Nov 12	Feng M	doi: 10.1186/s13046-018-0947-4.
29384225	Jolkinolide B inhibits glycolysis by downregulating hexokinase 2 expression through inactivating the Akt/mTOR pathway in non-small cell lung cancer cells.	J Cell Biochem	2018 Jun	Gao X	doi: 10.1002/jcb.26742
29978580	Functional variant of MTOR rs2536 and survival of Chinese gastric cancer patients.	Int J Cancer	2019 Jan 15	Cheng L	doi: 10.1002/ijc.31656
30755508	Repression of Human Papillomavirus Oncogene Expression under Hypoxia Is Mediated by PI3K/mTORC2/AKT Signaling.	MBio	2019 Feb 12	Bossler F	doi: 10.1128/mBio.02323-18.
29408410	The role of mTOR-mediated signaling in the regulation of cellular migration.	Immunol Lett	2018 Apr	Holroyd AK	doi: 10.1016/j.imlet.2018.01.015

Differential Expression

Expression in 33 cancers

Mutations

Cancer	Chr	Position	Mutation Type	dbSNP	Protein-change	Allele Freq
BLCA	chr1	11199661	Silent	NA	L1329L	0.17
BLCA	chr1	11209408	Silent	novel	R1235R	0.23
BLCA	chr1	11130544	Missense_Mutation	novel	Q1866H	0.2
BLCA	chr1	11122068	Missense_Mutation	novel	P2241S	0.22
BLCA	chr1	11130609	Missense_Mutation	rs762176419	E1845K	0.44
BLCA	chr1	11134452	Silent	novel	Q1715Q	0.39
BLCA	chr1	11124535	Missense_Mutation	NA	L2209V	0.16
BLCA	chr1	11237901	Missense_Mutation	rs566273004	R717Q	0.29
BLCA	chr1	11228833	Silent	NA	L955L	0.21
BLCA	chr1	11146701	Missense_Mutation	novel	Q1554L	0.1
BLCA	chr1	11259320	Missense_Mutation	novel	K30N	0.32
BLCA	chr1	11248089	Silent	novel	L282L	0.13
BLCA	chr1	11210832	Silent	NA	L1212L	0.34
BLCA	chr1	11129800	Silent	novel	A1884A	0.39
BLCA	chr1	11108178	Splice_Region	novel		0.41
BLCA	chr1	11228731	Missense_Mutation	novel	F989L	0.36
BRCA	chr1	11128041	Missense_Mutation	novel	C1999F	0.4
BRCA	chr1	11157256	Silent	NA	E1455E	0.32
BRCA	chr1	11144685	Missense_Mutation	NA	R1612P	0.23
BRCA	chr1	11127059	Missense_Mutation	NA	W2101L	0.38
BRCA	chr1	11259385	Missense_Mutation	rs769877976	A9T	0.68
BRCA	chr1	11150146	Missense_Mutation	NA	A1517V	0.29
BRCA	chr1	11241670	Missense_Mutation	novel	A475G	0.34
BRCA	chr1	11240526	Silent	NA	L521L	0.47
BRCA	chr1	11122122	Nonsense_Mutation	novel	Q2223*	0.37
BRCA	chr1	11114403	Silent	novel	E2405E	0.06
BRCA	chr1	11114815	Missense_Mutation	NA	E2388Q	0.14
BRCA	chr1	11109320	Missense_Mutation	NA	I2500F	0.78
BRCA	chr1	11210824	Missense_Mutation	NA	R1215T	0.22
BRCA	chr1	11146713	Missense_Mutation	novel	L1550Q	0.09
BRCA	chr1	11128120	Missense_Mutation	NA	I1973F	0.61
BRCA	chr1	11117042	Silent	NA	V2326V	0.27
BRCA	chr1	11228860	Silent	NA	F946F	0.22
BRCA	chr1	11133168	Missense_Mutation	novel	L1759R	0.44
BRCA	chr1	11213542	Missense_Mutation	NA	I1048L	0.27
BRCA	chr1	11234260	Missense_Mutation	NA	L738F	0.28
BRCA	chr1	11114872	Missense_Mutation	novel	E2369Q	0.51
BRCA	chr1	11108184	Missense_Mutation	novel	G2544A	0.07
BRCA	chr1	11129773	Silent	novel	S1893S	0.13
BRCA	chr1	11209391	Missense_Mutation	novel	Q1241R	0.05
BRCA	chr1	11247689	Silent	NA	L387L	0.4
BRCA	chr1	11114874	Missense_Mutation	NA	R2368Q	0.22
BRCA	chr1	11257040	Missense_Mutation	NA	L133V	0.56
BRCA	chr1	11127798	Silent	NA	E2014E	0.24
BRCA	chr1	11210856	Silent	novel	I1204I	0.08
CESC	chr1	11128121	Silent	NA	L1972L	0.23
CESC	chr1	11106644	3'UTR	novel		0.17
CESC	chr1	11107453	3'UTR	novel		0.23
CESC	chr1	11157220	Missense_Mutation	NA	M1467I	0.24
CESC	chr1	11124516	Missense_Mutation	NA	S2215Y	0.39
CESC	chr1	11213490	Frame_Shift_Del	novel	*G1065Vfs10**	0.21
CESC	chr1	11130747	Missense_Mutation	NA	E1799K	0.43
CESC	chr1	11108239	Missense_Mutation	NA	E2526K	0.16
CESC	chr1	11121339	Silent	NA	L2280L	0.31
CESC	chr1	11114363	Missense_Mutation	rs587777900	E2419K	0.47
CESC	chr1	11121339	Silent	NA	L2280L	0.27
CESC	chr1	11231307	Missense_Mutation	novel	R881H	0.13
CESC	chr1	11124589	Missense_Mutation	NA	D2191H	0.28
CESC	chr1	11209387	Silent	novel	G1242G	0.26
CESC	chr1	11124516	Missense_Mutation	rs587777894	S2215F	0.35
CESC	chr1	11124604	Missense_Mutation	novel	L2186V	0.32
CESC	chr1	11243187	Missense_Mutation	NA	E447Q	0.39
COAD	chr1	11130747	Missense_Mutation	NA	E1799K	0.41
COAD	chr1	11124516	Missense_Mutation	rs587777894	S2215F	0.65
COAD	chr1	11233409	Nonsense_Mutation	NA	E804*	0.36
COAD	chr1	11238462	Missense_Mutation	rs748207893	A648T	0.12
COAD	chr1	11213450	Missense_Mutation	rs757645678	M1078I	0.28
COAD	chr1	11114399	Silent	novel	L2407L	0.14
COAD	chr1	11213497	Missense_Mutation	novel	L1063F	0.3
COAD	chr1	11130675	Missense_Mutation	novel	A1823T	0.3
COAD	chr1	11126643	Missense_Mutation	novel	P2169S	0.43
COAD	chr1	11130661	Silent	rs769197073	N1827N	0.36
COAD	chr1	11117004	Missense_Mutation	novel	R2339I	0.08
COAD	chr1	11240523	Silent	rs369221365	Y522Y	0.49
COAD	chr1	11240377	Missense_Mutation	rs749766561	T571M	0.27
COAD	chr1	11117021	Missense_Mutation	NA	I2333M	0.36
COAD	chr1	11139308	Missense_Mutation	rs587777895	R1709H	0.4
COAD	chr1	11259252	Missense_Mutation	NA	R53Q	0.2
COAD	chr1	11144673	Missense_Mutation	NA	R1616H	0.27
COAD	chr1	11259350	Silent	novel	S20S	0.2
COAD	chr1	11216158	Missense_Mutation	NA	T1036N	0.12
COAD	chr1	11124516	Missense_Mutation	rs587777894	S2215F	0.22
COAD	chr1	11231353	Missense_Mutation	novel	E866K	0.18
COAD	chr1	11129784	Missense_Mutation	NA	R1890C	0.4
COAD	chr1	11209382	Missense_Mutation	NA	A1244E	0.28
COAD	chr1	11253930	Missense_Mutation	NA	A250V	0.39
COAD	chr1	11128037	Silent	novel	E2000E	0.1
COAD	chr1	11243121	Missense_Mutation	rs763879621	A469T	0.3
COAD	chr1	11233453	Missense_Mutation	novel	D789V	0.24
COAD	chr1	11243143	Silent	rs753907829	A461A	0.24
COAD	chr1	11259349	Missense_Mutation	rs149221273	V21I	0.25
COAD	chr1	11122122	Missense_Mutation	NA	Q2223K	0.57
COAD	chr1	11237963	Missense_Mutation	NA	L696F	0.18
COAD	chr1	11128926	Missense_Mutation	NA	G1914C	0.47
COAD	chr1	11145002	Missense_Mutation	NA	A1577V	0.44
COAD	chr1	11213446	Missense_Mutation	rs751901845	R1080C	0.44
COAD	chr1	11232487	Frame_Shift_Del	NA	*F821Lfs34**	0.28
COAD	chr1	11257151	Missense_Mutation	novel	V96M	0.31
COAD	chr1	11248003	Missense_Mutation	rs150146024	R311H	0.17
COAD	chr1	11259343	Nonsense_Mutation	novel	Q23*	0.3
COAD	chr1	11157182	Missense_Mutation	rs780930764	R1480H	0.28
COAD	chr1	11130767	Missense_Mutation	NA	A1792V	0.35
COAD	chr1	11112896	Missense_Mutation	NA	R2441Q	0.69
COAD	chr1	11107442	3'UTR	novel		0.12
COAD	chr1	11238594	Missense_Mutation	NA	R604C	0.39
COAD	chr1	11256029	Missense_Mutation	novel	R223H	0.07
COAD	chr1	11107467	3'UTR	rs768735847		0.22
COAD	chr1	11228722	Missense_Mutation	novel	Q992H	0.33
COAD	chr1	11258503	Missense_Mutation	novel	G85S	0.27
COAD	chr1	11204597	Missense_Mutation	novel	C1303F	0.62
COAD	chr1	11130747	Missense_Mutation	NA	E1799K	0.55
COAD	chr1	11167480	Missense_Mutation	NA	G1431R	0.38
COAD	chr1	11126713	Silent	novel	D2145D	0.08
COAD	chr1	11127775	Missense_Mutation	novel	L2022P	0.24
COAD	chr1	11167494	Missense_Mutation	rs35509012	P1426L	0.18
DLBC	chr1	11139632	Nonsense_Mutation	novel	W1633*	0.09
ESCA	chr1	11127746	Missense_Mutation	novel	E2032K	0.46
ESCA	chr1	11232486	Missense_Mutation	novel	I822V	0.25
ESCA	chr1	11117008	Missense_Mutation	novel	D2338N	0.37
ESCA	chr1	11228901	Missense_Mutation	novel	E933K	0.27
ESCA	chr1	11144648	Missense_Mutation	novel	Q1624H	0.46
GBM	chr1	11209330	Missense_Mutation	novel	S1261R	0.04
GBM	chr1	11199628	Missense_Mutation	novel	S1340R	0.07
GBM	chr1	11107408	3'UTR	novel		0.16
GBM	chr1	11199267	Missense_Mutation	novel	S1415F	0.47
GBM	chr1	11124517	Missense_Mutation	novel	S2215T	0.87
GBM	chr1	11144995	Frame_Shift_Del	novel	*A1579Gfs69**	0.43
GBM	chr1	11114338	Missense_Mutation	NA	L2427Q	0.3
GBM	chr1	11130571	Missense_Mutation	novel	E1857D	0.16
GBM	chr1	11130875	Intron	novel		0.16
GBM	chr1	11256144	Nonsense_Mutation	NA	Q185*	0.25
GBM	chr1	11130815	Intron	novel		0.09
GBM	chr1	11130587	Missense_Mutation	novel	E1852V	0.14
GBM	chr1	11107400	3'UTR	novel		0.69
GBM	chr1	11134372	Missense_Mutation	novel	E1742G	0.05
GBM	chr1	11130747	Missense_Mutation	NA	E1799K	0.27
HNSC	chr1	11228799	Missense_Mutation	novel	H967Y	0.35
HNSC	chr1	11129759	Missense_Mutation	novel	N1898S	0.13
HNSC	chr1	11146791	Missense_Mutation	novel	G1524V	0.29
HNSC	chr1	11259283	Nonsense_Mutation	novel	E43*	0.17
HNSC	chr1	11107342	3'UTR	novel		0.11
HNSC	chr1	11238600	Missense_Mutation	novel	F602L	0.53
HNSC	chr1	11126634	Missense_Mutation	novel	L2172M	0.41
HNSC	chr1	11127094	Missense_Mutation	rs542723817	M2089I	0.17
HNSC	chr1	11139643	Missense_Mutation	novel	V1630I	0.2
HNSC	chr1	11237925	Missense_Mutation	novel	E709G	0.26
KICH	chr1	11127790	Missense_Mutation	novel	I2017T	0.33
KICH	chr1	11114338	Missense_Mutation	NA	L2427R	0.3
KIRC	chr1	11128107	Missense_Mutation	rs587777893	T1977K	0.36
KIRC	chr1	11122106	Missense_Mutation	NA	I2228T	0.46
KIRC	chr1	11157246	Missense_Mutation	NA	A1459P	0.23
KIRC	chr1	11128107	Missense_Mutation	NA	T1977R	0.24
KIRC	chr1	11114324	In_Frame_Del	novel	R2430_L2431del	0.1
KIRC	chr1	11157173	Missense_Mutation	rs786205165	C1483F	0.04
KIRC	chr1	11157242	Missense_Mutation	NA	L1460P	0.31
KIRC	chr1	11247835	Missense_Mutation	novel	E367V	0.32
KIRC	chr1	11157265	Missense_Mutation	NA	K1452N	0.3
KIRC	chr1	11234211	Missense_Mutation	novel	R755C	0.26
KIRC	chr1	11157173	Missense_Mutation	NA	C1483Y	0.21
KIRC	chr1	11128107	Missense_Mutation	NA	T1977R	0.23
KIRC	chr1	11114354	Missense_Mutation	NA	V2422I	0.4
KIRC	chr1	11109318	Missense_Mutation	NA	I2500M	0.22
KIRC	chr1	11167473	Missense_Mutation	NA	L1433S	0.28
KIRC	chr1	11117020	Missense_Mutation	NA	L2334V	0.13
KIRC	chr1	11114402	Missense_Mutation	NA	V2406M	0.31
KIRC	chr1	11157233	Missense_Mutation	NA	Y1463S	0.18
KIRC	chr1	11129788	Missense_Mutation	NA	F1888L	0.5
KIRC	chr1	11130637	Silent	rs765484322	A1835A	0.08
KIRC	chr1	11231369	Missense_Mutation	NA	K860N	0.04
KIRC	chr1	11128120	Missense_Mutation	NA	I1973F	0.11
KIRC	chr1	11150141	Missense_Mutation	NA	A1519T	0.21
KIRC	chr1	11124516	Missense_Mutation	NA	S2215Y	0.6
KIRC	chr1	11108237	Silent	NA	E2526E	0.25
KIRP	chr1	11247733	Missense_Mutation	NA	V373L	0.22
KIRP	chr1	11210832	Silent	NA	L1212L	0.11
KIRP	chr1	11213546	Silent	NA	T1046T	0.39
KIRP	chr1	11114338	Missense_Mutation	NA	L2427Q	0.32
KIRP	chr1	11124516	Missense_Mutation	NA	S2215Y	0.32
LAML	chr1	11133170	Missense_Mutation	novel	Q1758H	0.19
LAML	chr1	11233413	Silent	novel	I802I	0.05
LAML	chr1	11243231	Missense_Mutation	rs199646229	A432V	0.18
LAML	chr1	11130609	Missense_Mutation	rs762176419	E1845K	0.14
LGG	chr1	11117039	Missense_Mutation	NA	M2327I	0.75
LGG	chr1	11124584	Silent	NA	L2192L	0.21
LGG	chr1	11122101	Missense_Mutation	NA	L2230V	0.79
LGG	chr1	11122082	Missense_Mutation	novel	L2236H	0.53
LGG	chr1	11145029	Missense_Mutation	novel	R1568M	0.32
LGG	chr1	11121269	Missense_Mutation	novel	W2304R	0.31
LGG	chr1	11124513	Missense_Mutation	NA	L2216P	0.83
LIHC	chr1	11109317	Missense_Mutation	NA	I2501F	0.08
LIHC	chr1	11144737	Missense_Mutation	NA	M1595V	0.68
LIHC	chr1	11238043	Missense_Mutation	NA	D670H	0.32
LIHC	chr1	11256931	Splice_Site	NA	X168_splice	0.67
LIHC	chr1	11241592	Missense_Mutation	novel	I501N	0.32
LIHC	chr1	11124516	Missense_Mutation	NA	S2215Y	0.13
LUAD	chr1	11124617	Silent	rs17229235	E2181E	0.24
LUAD	chr1	11232437	Missense_Mutation	NA	Q838L	0.17
LUAD	chr1	11167493	Silent	NA	P1426P	0.05
LUAD	chr1	11248023	Missense_Mutation	NA	M304I	0.11
LUAD	chr1	11107457	3'UTR	novel		0.09
LUAD	chr1	11167488	Missense_Mutation	NA	A1428V	0.39
LUAD	chr1	11139611	Silent	novel	R1640R	0.08
LUAD	chr1	11259353	Silent	novel	V19V	0.21
LUAD	chr1	11210831	Missense_Mutation	NA	I1213V	0.2
LUAD	chr1	11107473	3'UTR	novel		0.21
LUAD	chr1	11240376	Silent	NA	T571T	0.35
LUAD	chr1	11243156	Missense_Mutation	novel	D457G	0.27
LUAD	chr1	11124543	Missense_Mutation	NA	N2206S	0.12
LUAD	chr1	11231376	Missense_Mutation	NA	Y858C	0.13
LUAD	chr1	11121264	Silent	novel	L2305L	0.12
LUAD	chr1	11157156	Nonsense_Mutation	novel	E1489*	0.25
LUAD	chr1	11240413	Missense_Mutation	novel	K559M	0.07
LUAD	chr1	11257159	Frame_Shift_Ins	novel	*L93Pfs27**	0.39
LUAD	chr1	11238576	Missense_Mutation	novel	F610L	0.11
LUAD	chr1	11157226	Missense_Mutation	NA	K1465N	0.06
LUAD	chr1	11134415	Missense_Mutation	NA	A1728S	0.57
LUAD	chr1	11238402	Missense_Mutation	NA	D668Y	0.33
LUAD	chr1	11240482	Missense_Mutation	NA	Q536P	0.32
LUAD	chr1	11122037	Missense_Mutation	NA	R2251Q	0.16
LUAD	chr1	11237935	Missense_Mutation	NA	E706Q	0.11
LUAD	chr1	11259388	Missense_Mutation	NA	A8S	0.64
LUAD	chr1	11204665	Missense_Mutation	NA	W1280C	0.3
LUAD	chr1	11237906	Silent	NA	V715V	0.4
LUAD	chr1	11258539	Missense_Mutation	novel	E73Q	0.05
LUAD	chr1	11204629	Silent	novel	L1292L	0.11
LUAD	chr1	11213552	Missense_Mutation	rs532979867	M1044I	0.21
LUAD	chr1	11228671	Silent	novel	R1009R	0.16
LUAD	chr1	11212421	Missense_Mutation	rs151082401	Y1151C	0.17
LUAD	chr1	11121334	Missense_Mutation	novel	Q2282R	0.22
LUAD	chr1	11210815	Missense_Mutation	novel	K1218M	0.27
LUAD	chr1	11253917	Silent	novel	G254G	0.51
LUAD	chr1	11115436	Missense_Mutation	novel	S2350I	0.05
LUAD	chr1	11121293	Missense_Mutation	novel	G2296W	0.18
LUAD	chr1	11228828	Missense_Mutation	NA	R957Q	0.36
LUAD	chr1	11256105	Missense_Mutation	novel	V198L	0.39
LUAD	chr1	11121992	Missense_Mutation	NA	R2266P	0.23
LUSC	chr1	11133157	Missense_Mutation	NA	G1763C	0.21
LUSC	chr1	11133158	Missense_Mutation	NA	Q1762H	0.22
LUSC	chr1	11124532	Missense_Mutation	NA	A2210P	0.46
LUSC	chr1	11114401	Missense_Mutation	NA	V2406A	0.31
LUSC	chr1	11199340	Nonsense_Mutation	novel	R1391*	0.11
LUSC	chr1	11117055	Missense_Mutation	novel	R2322H	0.08
LUSC	chr1	11131321	Intron	novel		0.63
LUSC	chr1	11109683	Silent	novel	T2471T	0.22
LUSC	chr1	11253916	Missense_Mutation	novel	M255V	0.6
LUSC	chr1	11126674	Silent	rs201488400	P2158P	0.16
LUSC	chr1	11157275	Missense_Mutation	novel	W1449S	0.08
LUSC	chr1	11247643	Nonsense_Mutation	NA	R403*	0.23
LUSC	chr1	11237879	Silent	NA	A724A	0.38
LUSC	chr1	11237939	Silent	novel	V704V	0.22
LUSC	chr1	11114884	Missense_Mutation	novel	A2365S	0.26
LUSC	chr1	11237956	Missense_Mutation	NA	A699P	0.6
LUSC	chr1	11258552	Missense_Mutation	NA	N68K	0.27
LUSC	chr1	11237847	Missense_Mutation	NA	I735S	0.19
LUSC	chr1	11238584	Missense_Mutation	NA	A607V	0.35
LUSC	chr1	11128926	Missense_Mutation	novel	G1914R	0.18
LUSC	chr1	11121365	Missense_Mutation	NA	A2272S	0.21
LUSC	chr1	11228801	Missense_Mutation	novel	H966R	0.2
LUSC	chr1	11127752	Missense_Mutation	novel	G2030S	0.13
OV	chr1	11139545	Silent	novel	K1662K	0.15
OV	chr1	11234213	Missense_Mutation	NA	A754G	0.32
OV	chr1	11259267	In_Frame_Ins	novel	V48delinsANERKGGILAI	0.1
OV	chr1	11128041	Missense_Mutation	novel	C1999F	0.08
OV	chr1	11139545	Silent	novel	K1662K	0.07
OV	chr1	11127656	Missense_Mutation	novel	P2062S	0.11
OV	chr1	11248093	Missense_Mutation	rs757384321	R281H	0.15
OV	chr1	11139425	Missense_Mutation	novel	H1670R	0.04
OV	chr1	11240431	Missense_Mutation	NA	R553H	0.07
OV	chr1	11114454	Splice_Site	novel	X2389_splice	0.29
OV	chr1	11157240	Missense_Mutation	NA	V1461L	0.86
OV	chr1	11247826	Missense_Mutation	NA	F370Y	0.23
OV	chr1	11122031	Missense_Mutation	novel	Y2253F	0.12
OV	chr1	11231326	Missense_Mutation	NA	E875K	0.18
OV	chr1	11234175	Missense_Mutation	novel	L767V	0.03
OV	chr1	11127794	Frame_Shift_Ins	novel	*L2016Tfs10**	0.16
OV	chr1	11243230	Silent	novel	A432A	0.1
OV	chr1	11209314	Missense_Mutation	novel	K1267Q	0.04
OV	chr1	11128104	Missense_Mutation	novel	V1978E	0.02
OV	chr1	11157198	Missense_Mutation	novel	E1475Q	0.09
OV	chr1	11157199	Silent	novel	P1474P	0.08
OV	chr1	11259289	Missense_Mutation	rs758668050	A41S	0.61
OV	chr1	11146727	Missense_Mutation	novel	F1545L	0.05
OV	chr1	11258525	Missense_Mutation	novel	S77R	0.19
OV	chr1	11248007	Missense_Mutation	novel	P310S	0.07
OV	chr1	11212881	Missense_Mutation	rs529153687	A1105T	0.79
PAAD	chr1	11133086	Missense_Mutation	novel	W1786C	0.08
PAAD	chr1	11107426	3'UTR	novel		0.16
PAAD	chr1	11134464	Splice_Region	rs769706061	I1711I	0.11
PAAD	chr1	11210873	Missense_Mutation	novel	L1199M	0.17
PAAD	chr1	11257005	Silent	rs757191894	Y144Y	0.16
PAAD	chr1	11231047	Missense_Mutation	rs376873727	R886H	0.27
PCPG	chr1	11109320	Missense_Mutation	NA	I2500F	0.23
PRAD	chr1	11150192	Missense_Mutation	rs748220176	T1502A	0.19
PRAD	chr1	11256075	Nonsense_Mutation	novel	G208*	0.07
PRAD	chr1	11130550	Silent	rs762660728	P1864P	0.08
PRAD	chr1	11128107	Missense_Mutation	NA	T1977R	0.06
PRAD	chr1	11129773	Silent	novel	S1893S	0.26
PRAD	chr1	11130633	Missense_Mutation	novel	T1837A	0.35
PRAD	chr1	11199636	Missense_Mutation	novel	I1338L	0.48
PRAD	chr1	11209410	Missense_Mutation	novel	R1235W	0.43
READ	chr1	11130646	Silent	novel	A1832A	0.14
READ	chr1	11109305	Nonsense_Mutation	NA	R2505*	0.1
READ	chr1	11128947	Missense_Mutation	NA	L1907F	0.48
SKCM	chr1	11240381	Missense_Mutation	NA	L570F	0.54
SKCM	chr1	11130747	Missense_Mutation	NA	E1799K	0.48
SKCM	chr1	11240437	Missense_Mutation	NA	P551L	0.48
SKCM	chr1	11128943	Missense_Mutation	novel	T1908I	0.25
SKCM	chr1	11127683	Missense_Mutation	novel	P2053A	0.36
SKCM	chr1	11109320	Missense_Mutation	NA	I2500F	0.06
SKCM	chr1	11259392	Silent	NA	P6P	0.14
SKCM	chr1	11212881	Missense_Mutation	rs529153687	A1105T	0.21
SKCM	chr1	11238037	Missense_Mutation	NA	R672C	0.24
SKCM	chr1	11230944	Silent	NA	S920S	0.38
SKCM	chr1	11144678	Silent	novel	I1614I	0.27
SKCM	chr1	11117042	Silent	NA	V2326V	0.28
SKCM	chr1	11126694	Missense_Mutation	rs752458445	R2152C	0.32
SKCM	chr1	11129784	Missense_Mutation	NA	R1890C	0.14
SKCM	chr1	11139608	Silent	NA	S1641S	0.28
SKCM	chr1	11144674	Missense_Mutation	rs17848545	R1616C	0.25
SKCM	chr1	11139355	Silent	NA	H1693H	0.73
SKCM	chr1	11134374	Silent	novel	Q1741Q	0.31
SKCM	chr1	11167492	Missense_Mutation	novel	E1427K	0.57
SKCM	chr1	11247873	Silent	novel	S354S	0.27
SKCM	chr1	11257130	Missense_Mutation	novel	R103G	0.25
SKCM	chr1	11114371	Missense_Mutation	NA	A2416V	0.52
SKCM	chr1	11121364	Missense_Mutation	NA	A2272V	0.32
SKCM	chr1	11240343	Silent	novel	I582I	0.42
SKCM	chr1	11126686	Silent	rs201706131	Q2154Q	0.46
SKCM	chr1	11238480	Missense_Mutation	NA	H642Y	0.18
SKCM	chr1	11233434	Silent	NA	I795I	0.05
SKCM	chr1	11240541	Silent	NA	A516A	0.3
SKCM	chr1	11240450	Missense_Mutation	NA	L547F	0.51
SKCM	chr1	11114348	Missense_Mutation	novel	D2424N	0.09
SKCM	chr1	11238511	In_Frame_Ins	novel	T631_P632insA	0.03
SKCM	chr1	11243224	Silent	NA	F434F	0.26
SKCM	chr1	11109371	Splice_Site	NA	X2483_splice	0.43
SKCM	chr1	11114359	Missense_Mutation	NA	A2420V	0.39
SKCM	chr1	11127130	Missense_Mutation	NA	D2077E	0.3
SKCM	chr1	11228756	Missense_Mutation	novel	S981F	0.48
SKCM	chr1	11256024	Missense_Mutation	novel	P225S	0.4
SKCM	chr1	11240437	Missense_Mutation	NA	P551L	0.42
SKCM	chr1	11247695	Silent	novel	N385N	0.17
SKCM	chr1	11247696	Missense_Mutation	novel	N385I	0.17
SKCM	chr1	11139369	Silent	NA	L1689L	0.58
SKCM	chr1	11128018	Nonsense_Mutation	NA	Q2007*	0.29
SKCM	chr1	11139609	Missense_Mutation	rs772556623	S1641F	0.28
SKCM	chr1	11126684	Missense_Mutation	NA	S2155F	0.16
SKCM	chr1	11130667	Silent	NA	I1825I	0.18
SKCM	chr1	11228916	Missense_Mutation	NA	D928N	0.32
SKCM	chr1	11124540	Missense_Mutation	NA	T2207I	0.28
SKCM	chr1	11130573	Missense_Mutation	rs779045714	E1857K	0.88
SKCM	chr1	11139644	Silent	rs186504696	I1629I	0.24
SKCM	chr1	11139608	Silent	NA	S1641S	0.41
SKCM	chr1	11139609	Missense_Mutation	rs772556623	S1641F	0.41
SKCM	chr1	11204701	Splice_Region	NA	A1268A	0.23
SKCM	chr1	11213459	Silent	NA	I1075I	0.54
SKCM	chr1	11126768	Missense_Mutation	NA	S2127F	0.67
SKCM	chr1	11129751	Nonsense_Mutation	novel	Q1901*	0.12
SKCM	chr1	11256986	Silent	NA	R151R	0.27
STAD	chr1	11212346	Missense_Mutation	rs557533784	T1176M	0.26
STAD	chr1	11240523	Silent	rs369221365	Y522Y	0.23
STAD	chr1	11243280	Missense_Mutation	NA	T416A	0.44
STAD	chr1	11144649	Missense_Mutation	novel	Q1624R	0.1
STAD	chr1	11230961	Missense_Mutation	novel	V915F	0.25
STAD	chr1	11115469	Splice_Site	NA	X2339_splice	0.25
STAD	chr1	11213489	Frame_Shift_Ins	novel	E1066*	0.21
STAD	chr1	11124583	Missense_Mutation	NA	R2193C	0.15
STAD	chr1	11144650	Nonsense_Mutation	NA	Q1624*	0.18
STAD	chr1	11243148	Nonsense_Mutation	NA	R460*	0.32
STAD	chr1	11247699	Missense_Mutation	NA	K384R	0.34
STAD	chr1	11209451	Missense_Mutation	novel	T1221I	0.38
STAD	chr1	11241663	Missense_Mutation	NA	Q477H	0.36
STAD	chr1	11230975	Missense_Mutation	NA	R910Q	0.21
STAD	chr1	11108220	Missense_Mutation	NA	A2532V	0.28
STAD	chr1	11109318	Missense_Mutation	NA	I2500M	0.31
STAD	chr1	11238594	Missense_Mutation	NA	R604C	0.34
STAD	chr1	11253900	Missense_Mutation	novel	R260Q	0.13
STAD	chr1	11253880	Missense_Mutation	NA	I267V	0.09
STAD	chr1	11210861	Nonsense_Mutation	NA	R1203*	0.29
STAD	chr1	11213531	Silent	rs147272284	T1051T	0.21
STAD	chr1	11121360	Silent	NA	P2273P	0.08
STAD	chr1	11240377	Missense_Mutation	rs749766561	T571M	0.36
STAD	chr1	11238576	Missense_Mutation	NA	F610V	0.11
STAD	chr1	11243114	Missense_Mutation	NA	K471T	0.28
STAD	chr1	11121288	Silent	rs763361130	D2297D	0.14
STAD	chr1	11121299	Missense_Mutation	NA	T2294A	0.13
STAD	chr1	11107460	3'UTR	rs376243307		0.42
STAD	chr1	11144673	Missense_Mutation	NA	R1616H	0.22
STAD	chr1	11253871	Missense_Mutation	NA	E270K	0.21
STAD	chr1	11122115	Missense_Mutation	novel	Y2225C	0.25
STAD	chr1	11144750	Missense_Mutation	NA	M1590I	0.06
STAD	chr1	11231308	Missense_Mutation	NA	R881C	0.33
STAD	chr1	11237887	Missense_Mutation	NA	N722D	0.4
STAD	chr1	11234178	Frame_Shift_Del	novel	*R766Dfs11**	0.11
STAD	chr1	11231417	Silent	NA	L844L	0.07
STAD	chr1	11243166	Missense_Mutation	novel	R454C	0.3
STAD	chr1	11228731	Silent	NA	F989F	0.15
STAD	chr1	11157177	Missense_Mutation	NA	R1482C	0.31
STAD	chr1	11213531	Silent	rs147272284	T1051T	0.31
STAD	chr1	11228828	Missense_Mutation	NA	R957Q	0.35
STAD	chr1	11124509	Silent	NA	R2217R	0.19
STAD	chr1	11248004	Missense_Mutation	rs200901835	R311C	0.19
STAD	chr1	11248094	Missense_Mutation	NA	R281C	0.18
THCA	chr1	11258567	Frame_Shift_Ins	novel	*F63Lfs7**	0.05
THYM	chr1	11109684	Missense_Mutation	NA	T2471M	0.32
UCEC	chr1	11108247	Missense_Mutation	NA	T2523M	0.57
UCEC	chr1	11128467	Missense_Mutation	NA	R1966Q	0.22
UCEC	chr1	11109318	Missense_Mutation	NA	I2500M	0.37
UCEC	chr1	11253871	Missense_Mutation	NA	E270K	0.32
UCEC	chr1	11257065	Missense_Mutation	NA	E124D	0.31
UCEC	chr1	11146754	Silent	NA	I1536I	0.33
UCEC	chr1	11248073	Nonsense_Mutation	novel	E288*	0.07
UCEC	chr1	11126694	Missense_Mutation	rs752458445	R2152C	0.14
UCEC	chr1	11130675	Missense_Mutation	novel	A1823T	0.08
UCEC	chr1	11234168	Missense_Mutation	rs753826002	R769H	0.28
UCEC	chr1	11128096	Missense_Mutation	NA	K1981E	0.25
UCEC	chr1	11124516	Missense_Mutation	NA	S2215Y	0.26
UCEC	chr1	11144745	Missense_Mutation	NA	S1592Y	0.47
UCEC	chr1	11247698	Missense_Mutation	NA	K384N	0.31
UCEC	chr1	11106681	3'UTR	novel		0.53
UCEC	chr1	11139643	Missense_Mutation	novel	V1630I	0.38
UCEC	chr1	11247725	Silent	novel	Q375Q	0.46
UCEC	chr1	11259326	Silent	novel	G28G	0.29
UCEC	chr1	11130747	Missense_Mutation	NA	E1799K	0.46
UCEC	chr1	11256117	Missense_Mutation	NA	I194V	0.46
UCEC	chr1	11106900	3'UTR	novel		0.38
UCEC	chr1	11109305	Nonsense_Mutation	NA	R2505*	0.4
UCEC	chr1	11124516	Missense_Mutation	NA	S2215Y	0.4
UCEC	chr1	11130641	Missense_Mutation	rs142403193	T1834M	0.5
UCEC	chr1	11114875	Nonsense_Mutation	novel	R2368*	0.13
UCEC	chr1	11124516	Missense_Mutation	NA	S2215Y	0.41
UCEC	chr1	11199302	Missense_Mutation	novel	E1403D	0.52
UCEC	chr1	11256156	Missense_Mutation	novel	T181A	0.45
UCEC	chr1	11130747	Missense_Mutation	NA	E1799K	0.43
UCEC	chr1	11129788	Missense_Mutation	NA	F1888L	0.24
UCEC	chr1	11199654	Missense_Mutation	NA	D1332N	0.13
UCEC	chr1	11232447	Missense_Mutation	NA	A835S	0.24
UCEC	chr1	11257129	Missense_Mutation	rs763230714	R103Q	0.23
UCEC	chr1	11129810	Missense_Mutation	NA	T1881M	0.12
UCEC	chr1	11228694	Nonsense_Mutation	novel	R1002*	0.18
UCEC	chr1	11238424	Silent	rs749797494	L660L	0.25
UCEC	chr1	11108281	Missense_Mutation	NA	D2512Y	0.53
UCEC	chr1	11124503	Silent	novel	N2219N	0.17
UCEC	chr1	11233409	Nonsense_Mutation	NA	E804*	0.16
UCEC	chr1	11240513	Missense_Mutation	rs764486955	R526C	0.22
UCEC	chr1	11253971	Splice_Region	novel	H236H	0.04
UCEC	chr1	11257102	Missense_Mutation	novel	R112Q	0.17
UCEC	chr1	11109319	Missense_Mutation	NA	I2500N	0.18
UCEC	chr1	11108244	Missense_Mutation	NA	Q2524L	0.08
UCEC	chr1	11122048	Silent	rs779172738	H2247H	0.16
UCEC	chr1	11127673	Missense_Mutation	NA	A2056V	0.5
UCEC	chr1	11167482	Missense_Mutation	NA	A1430V	0.23
UCEC	chr1	11241656	Missense_Mutation	rs201601333	A480T	0.24
UCEC	chr1	11258492	Silent	NA	L88L	0.33
UCEC	chr1	11144748	Missense_Mutation	novel	V1591G	0.08
UCEC	chr1	11209410	Missense_Mutation	novel	R1235W	0.36
UCEC	chr1	11121328	Missense_Mutation	novel	V2284A	0.25
UCEC	chr1	11213473	Silent	novel	L1071L	0.08
UCEC	chr1	11238617	Missense_Mutation	novel	G596D	0.26
UCEC	chr1	11247652	Missense_Mutation	novel	A400T	0.29
UCEC	chr1	11124503	Frame_Shift_Ins	novel	*N2219Kfs26**	0.18
UCEC	chr1	11128857	Nonsense_Mutation	novel	Q1937*	0.18
UCEC	chr1	11106900	3'UTR	novel		0.4
UCEC	chr1	11230974	Silent	novel	R910R	0.22
UCEC	chr1	11233438	Missense_Mutation	novel	V794A	0.21
UCEC	chr1	11234168	Missense_Mutation	rs753826002	R769H	0.2
UCEC	chr1	11240516	Missense_Mutation	novel	S525G	0.37
UCEC	chr1	11128021	Missense_Mutation	NA	V2006I	0.28
UCEC	chr1	11117062	Missense_Mutation	novel	Y2320H	0.13
UCEC	chr1	11126714	Missense_Mutation	novel	D2145G	0.18
UCEC	chr1	11128526	Silent	novel	I1946I	0.52
UCEC	chr1	11134463	Missense_Mutation	rs759390743	D1712N	0.3
UCEC	chr1	11145044	Missense_Mutation	novel	C1563Y	0.46
UCEC	chr1	11157182	Missense_Mutation	rs780930764	R1480H	0.62
UCEC	chr1	11199340	Missense_Mutation	novel	R1391G	0.48
UCEC	chr1	11126694	Missense_Mutation	rs752458445	R2152C	0.44
UCEC	chr1	11127028	Silent	novel	I2111I	0.51
UCEC	chr1	11130850	Intron	rs761690668		0.43
UCEC	chr1	11231048	Missense_Mutation	novel	R886S	0.21
UCEC	chr1	11257129	Missense_Mutation	rs763230714	R103Q	0.57
UCEC	chr1	11130747	Missense_Mutation	NA	E1799K	0.18
UCEC	chr1	11128507	Missense_Mutation	NA	V1953L	0.04
UCEC	chr1	11144650	Nonsense_Mutation	NA	Q1624*	0.47
UCEC	chr1	11216200	Missense_Mutation	NA	F1022S	0.34
UCEC	chr1	11124516	Missense_Mutation	NA	S2215Y	0.32
UCEC	chr1	11128909	Silent	novel	V1919V	0.26
UCEC	chr1	11209397	Missense_Mutation	NA	S1239N	0.63
UCEC	chr1	11259287	Silent	novel	A41A	0.29
UCEC	chr1	11130747	Missense_Mutation	NA	E1799K	0.35
UCEC	chr1	11199603	Missense_Mutation	novel	D1349Y	0.22
UCEC	chr1	11130641	Missense_Mutation	rs142403193	T1834M	0.44
UCEC	chr1	11204614	Silent	rs760560620	S1297S	0.35
UCEC	chr1	11213415	Missense_Mutation	rs573466361	R1090H	0.27
UCEC	chr1	11228829	Missense_Mutation	novel	R957W	0.4
UCEC	chr1	11238549	Missense_Mutation	rs199712134	R619C	0.29
UCEC	chr1	11253862	Nonsense_Mutation	novel	R273*	0.4
UCEC	chr1	11238583	Silent	novel	A607A	0.56
UCEC	chr1	11212394	Missense_Mutation	NA	V1160G	0.21
UCEC	chr1	11106541	3'UTR	novel		0.41
UCEC	chr1	11112896	Missense_Mutation	NA	R2441Q	0.05
UCEC	chr1	11114418	Silent	novel	C2400C	0.41
UCEC	chr1	11257099	Missense_Mutation	novel	N113T	0.45
UCEC	chr1	11247903	Silent	rs762523375	G344G	0.36
UCEC	chr1	11127803	Missense_Mutation	NA	S2013G	0.44
UCEC	chr1	11114352	Silent	novel	V2422V	0.32
UCEC	chr1	11128107	Missense_Mutation	novel	T1977I	0.25
UCEC	chr1	11139392	Missense_Mutation	novel	P1681L	0.06
UCEC	chr1	11146771	Nonsense_Mutation	NA	E1531*	0.28
UCEC	chr1	11209428	Missense_Mutation	novel	P1229T	0.03
UCEC	chr1	11213486	Missense_Mutation	NA	E1066D	0.32
UCEC	chr1	11127750	Silent	novel	G2030G	0.28
UCEC	chr1	11124516	Missense_Mutation	NA	S2215Y	0.45
UCEC	chr1	11130621	Missense_Mutation	novel	T1841A	0.25
UCEC	chr1	11128116	Missense_Mutation	NA	Y1974C	0.47
UCEC	chr1	11108280	Missense_Mutation	NA	D2512G	0.16
UCEC	chr1	11127781	Missense_Mutation	novel	A2020V	0.08
UCEC	chr1	11139390	Missense_Mutation	novel	S1682A	0.07
UCEC	chr1	11127099	Missense_Mutation	NA	Y2088D	0.42
UCEC	chr1	11130747	Missense_Mutation	NA	E1799K	0.45
UCEC	chr1	11231033	Missense_Mutation	NA	L891V	0.34
UCEC	chr1	11129790	Missense_Mutation	NA	F1888V	0.4
UCEC	chr1	11128920	Missense_Mutation	novel	W1916R	0.23
UCEC	chr1	11139627	Missense_Mutation	NA	K1635T	0.23
UCEC	chr1	11121980	Missense_Mutation	rs752641006	R2270Q	0.07
UCEC	chr1	11128521	Missense_Mutation	NA	T1948M	0.23
UCEC	chr1	11150159	Missense_Mutation	NA	A1513T	0.66
UCEC	chr1	11212823	Missense_Mutation	rs759748160	A1124V	0.47
UCEC	chr1	11127673	Missense_Mutation	NA	A2056V	0.06
UCEC	chr1	11124516	Missense_Mutation	NA	S2215Y	0.3
UCEC	chr1	11134428	Silent	NA	T1723T	0.28
UCEC	chr1	11108219	Silent	novel	A2532A	0.21
UCEC	chr1	11109362	Missense_Mutation	novel	G2486S	0.22
UCEC	chr1	11122075	Silent	novel	G2238G	0.26
UCEC	chr1	11126694	Missense_Mutation	rs752458445	R2152C	0.21
UCEC	chr1	11127054	Missense_Mutation	novel	L2103I	0.28
UCEC	chr1	11209427	Missense_Mutation	novel	P1229H	0.51
UCEC	chr1	11212882	Silent	rs751480341	G1104G	0.19
UCEC	chr1	11231415	Missense_Mutation	novel	G845E	0.24
UCEC	chr1	11232483	Missense_Mutation	novel	I823L	0.3
UCEC	chr1	11238036	Missense_Mutation	novel	R672H	0.3
UCEC	chr1	11240357	Missense_Mutation	rs760445750	D578N	0.63
UCEC	chr1	11256080	Missense_Mutation	novel	R206H	0.38
UCEC	chr1	11129788	Missense_Mutation	NA	F1888L	0.44
UCEC	chr1	11248041	Silent	NA	K298K	0.28
UCEC	chr1	11234155	Missense_Mutation	NA	E773D	0.12
UCEC	chr1	11128909	Silent	novel	V1919V	0.32
UCEC	chr1	11130645	Missense_Mutation	novel	T1833A	0.43
UCEC	chr1	11247894	Silent	novel	T347T	0.4
UCEC	chr1	11199555	Missense_Mutation	novel	E1365K	0.42
UCEC	chr1	11257025	Missense_Mutation	novel	D138N	0.39

Copy Number Variations (CNVs)

Cancer	Type	Freq	Q-value
CESC	DEL	0.1119	0.00029523
CHOL	DEL	0.7778	3.3987e-23
DLBC	DEL	0.0833	0.011841
HNSC	DEL	0.1398	7.0766e-07
KIRC	DEL	0.1439	2.3538e-09
KIRP	DEL	0.1736	1.462e-09
LUAD	DEL	0.1473	0.0024765
LUSC	DEL	0.3653	2.5882e-07
MESO	DEL	0.3333	2.434e-07
READ	DEL	0.3939	2.1758e-10
TGCT	DEL	0.18	0.00046313
UCS	DEL	0.3214	0.0051125

Survival Analysis

Cancer	P-value	Q-value
KIRC	0.00064	Kaplan-Meier Survival Analysis
SARC	0.0026	Kaplan-Meier Survival Analysis
ACC	0.00049	Kaplan-Meier Survival Analysis
ESCA	0.038	Kaplan-Meier Survival Analysis
BLCA	0.038	Kaplan-Meier Survival Analysis
LAML	0.011	Kaplan-Meier Survival Analysis
UCEC	0.022	Kaplan-Meier Survival Analysis
LGG	0.0001	Kaplan-Meier Survival Analysis
OV	0.042	Kaplan-Meier Survival Analysis

Drugs

EuRBPDB

Description

RBPome

Literatures

Expression

Transcripts

Gene Model

Pathways

Phenotypes

GWAS

PPI

Gene Ontology

Select Dataset :

Input Drug :

Input Cell Line :

Eesembl ID

Cell lines and drugs in GSE70138 or GSE92742